

=> d his

(FILE 'HOME' ENTERED AT 09:19:30 ON 06 JUN 2005)

L1 FILE 'HCAPLUS' ENTERED AT 09:19:43 ON 06 JUN 2005  
1 US20020065296/PN OR US99-115878/AP,PRN

FILE 'REGISTRY' ENTERED AT 09:20:28 ON 06 JUN 2005

L2 FILE 'HCAPLUS' ENTERED AT 09:20:29 ON 06 JUN 2005  
TRA L1 1- RN : 157 TERMS

L3 FILE 'REGISTRY' ENTERED AT 09:20:30 ON 06 JUN 2005  
157 SEA L2

L4 FILE 'WPIX' ENTERED AT 09:20:35 ON 06 JUN 2005  
1 US20020065296/PN OR US99-115878/AP,PRN

=> b hcap

FILE 'HCAPLUS' ENTERED AT 09:22:07 ON 06 JUN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jun 2005 VOL 142 ISS 24  
FILE LAST UPDATED: 5 Jun 2005 (20050605/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all l1

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 2002:409267 HCAPLUS  
DN 137:6098  
ED Entered STN: 31 May 2002  
TI Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors  
IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Sibley, Robert N.;  
Hatoum-Mokdad, Holia; Monahan, Mary-katherine; Gunn, David E.; Lowinger,  
Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.  
PA Bayer Corporation, USA  
SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U. S. Ser. No. 778,039.  
CODEN: USXXCO  
DT Patent  
LA English  
IC ICM A61K031-506  
ICS A61K031-501; A61K031-497; A61K031-4725; A61K031-4709  
INCL 514310000  
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))  
Section cross-reference(s): 1  
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

Search done by Noble Jarrell

PI US 2002065296 A1 20020530 US 2001-838286 20010420 <--  
 US 2003139605 A1 20030724 US 2002-71248 20020211  
 CA 2443952 AA 20021031 CA 2002-2443952 20020417  
 WO 2002085859 A1 20021031 WO 2002-US12064 20020417  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 EP 1379507 A1 20040114 EP 2002-725709 20020417  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2004537511 T2 20041216 JP 2002-583386 20020417  
 PRAI US 1999-115878P P 19990113  
 US 1999-257265 B1 19990225  
 US 1999-425229 A2 19991022  
 US 2001-778039 A2 20010207  
 US 1999-115877P P 19990113  
 US 1999-257266 B2 19990225  
 US 1999-425228 B1 19991022  
 US 2001-838286 A 20010420  
 US 2001-948915 A1 20010910  
 WO 2002-US12064 W 20020417

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002065296	ICM	A61K031-506
	ICS	A61K031-501; A61K031-497; A61K031-4725; A61K031-4709
	INCL	514310000
US 2002065296	NCL	514/310.000; 514/313.000; 514/336.000; 514/337.000; 514/252.030; 514/252.040; 514/255.050; 514/256.000
	ECLA	A61K031/17; A61K031/18; A61K031/24; A61K031/341; A61K031/40+A; A61K031/4035; A61K031/44; A61K031/44+A; A61K031/4439; A61K031/4453; A61K031/47; A61K031/4709; A61K031/4725; A61K031/495+A; A61K031/496; A61K031/5375; A61K031/5377; C07D213/75D3; C07D215/38C; C07D217/22; C07D401/12+215+213 <--
US 2003139605	NCL	546/291.000
	ECLA	A61K031/17; C07C311/29; C07C317/22; C07D209/48D5C1; C07D213/75D3; C07D213/81E; C07D295/12A1; C07D295/12B1D4; C07D295/18B2D; A61K031/18; A61K031/24; A61K031/341; A61K031/40+A; A61K031/4035; A61K031/44+A; A61K031/4439; A61K031/4453; A61K031/495+A; A61K031/496; A61K031/5375; A61K031/5377; C07C275/28; C07C275/30; C07C275/32; C07C275/36; C07C275/40
WO 2002085859	ECLA	A61K031/44; A61K031/47; A61K031/4709; A61K031/4725; C07D213/75D3; C07D215/38C; C07D217/22; C07D401/12+215+213; C07D401/12+217+213
JP 2004537511	FTERM	4C031/JA09; 4C034/AL05; 4C055/AA01; 4C055/BA01; 4C055/BA02; 4C055/BA53; 4C055/BB17; 4C055/CA01; 4C055/DA06; 4C055/DA28; 4C055/DA42; 4C055/DA47; 4C055/DB10; 4C055/DB17; 4C055/EA01; 4C063/AA01; 4C063/BB07; 4C063/BB09; 4C063/CC14; 4C063/CC15; 4C063/DD07; 4C063/DD12; 4C063/EE01; 4C086/AA01; 4C086/AA03; 4C086/BC17; 4C086/BC28; 4C086/BC30; 4C086/BC50; 4C086/GA07; 4C086/GA08; 4C086/GA12; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA01; 4C086/ZA02; 4C086/ZA36; 4C086/ZA45; 4C086/ZA54; 4C086/ZA59; 4C086/ZA67; 4C086/ZA68; 4C086/ZA75; 4C086/ZA86; 4C086/ZA89; 4C086/ZA94; 4C086/ZA96; 4C086/ZA97; 4C086/ZB02; 4C086/ZB05; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB26; 4C086/ZB33;

4C086/ZB35; 4C086/ZC21; 4C086/ZC35

OS MARPAT 137:6098

- AB This invention relates to the use of a group of heteroaryl ureas (I; for example, N-(2-methoxy-3-quinolyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea) containing N in treating p38 mediated diseases, and pharmaceutical compns. for use in such therapy. I is A-NHC(O)NH-B or a pharmaceutically acceptable salt thereof, wherein A is a substituted or unsubstituted pyridyl, quinoliny or isoquinoliny group, B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 50 C atoms with a cyclic structure bound directly to N, containing at least 5 cyclic members with 0-4 members of groups consisting of N, O and S. Information about the substituents for A and B are given in the claims. Although the methods of preparation are not claimed, 37 example prepn. are included as well as examples of preparation of intermediates. No pharmacol. data is included.
- ST nitrogen heteroaryl urea prepn p38 kinase inhibitor; pyridyl urea prepn p38 kinase inhibitor; quinolyl urea prepn p38 kinase inhibitor; isoquinolyl urea prepn p38 kinase inhibitor
- IT Infection  
(Chagas' disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Inflammation  
(Crohn's disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Intestine, disease  
(Crohn's; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Disease, animal  
(Jarisch-Herxheimer reaction; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Malaria  
(Plasmodium falciparum malaria and cerebral malaria; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treating)
- IT Antimalarials  
(Plasmodium falciparum malaria and cerebral malaria; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)
- IT Toxins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Shiga-like toxin, effects of toxins from Escherichia coli infection; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Respiratory distress syndrome  
(adult; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Hepatitis  
(alc.; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Transplant rejection  
(allotransplant; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Lung  
(alveolus, injury; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)
- IT Aneurysm  
(aortic; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Meningitis  
(bacterial; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Necrosis  
(bowel; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38

kinase inhibitors for treatment of)

IT Bronchi, disease  
Inflammation  
(bronchitis, obliterative; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Injury  
(cerebral; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Pneumoconiosis  
(coal worker's; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Eye, disease  
(cornea, ulcer; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Ulcer  
(corneal; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Radiation  
(damage, injury/toxicity following administration of monoclonal antibodies; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Cartilage, disease  
(degeneration; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Multiple sclerosis  
(demyelination and oligiodendrocyte loss in; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Liver, disease  
(during acute inflammation; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Toxins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(enterotoxin A, effects of toxins from Staphylococcus infection; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Skin, disease  
(epidermolysis bullosa, dystrophobic; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Liver, disease  
(failure; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Lung, disease  
(fibrosis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Nervous system agents  
(for demyelating disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)

IT Wound healing  
(impaired wound healing in infection; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Helicobacter pylori  
(infection during peptic ulcer disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Borrelia burgdorferi  
Cytomegalovirus  
Human immunodeficiency virus  
Influenza virus  
Theiler's murine encephalomyelitis virus  
Treponema pallidum  
(infections from; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Brain, disease  
Reperfusion  
(injury; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Leukemia

(lymphocytic, inhibitors; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)

IT Neoplasm  
(metastasis, inhibitors; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)

IT Heterocyclic compounds  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(nitrogen, heteroaryl ureas; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)

IT Bone, disease  
(osteopenia, mediated by MMP activity; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Inflammation  
Pancreas, disease  
(pancreatitis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Ulcer  
(peptic, Helicobacter pylori infection during; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Osteoporosis  
(postmenopausal; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treating)

IT Human  
(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)

IT Allergy  
Alzheimer's disease  
Arthritis  
Asthma  
Diabetes mellitus  
Rheumatoid arthritis  
Tuberculosis  
(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treating)

IT Encephalitis  
Myelodysplastic syndromes  
Periodontium, disease  
Psoriasis  
Rheumatic fever  
Silicosis  
(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Allergy inhibitors  
Anti-Alzheimer's agents  
Anti-infective agents  
Anti-inflammatory agents  
Antiarthritics  
Antiasthmatics  
Antibacterial agents  
Anticoagulants  
Antidiabetic agents  
Antirheumatic agents  
Antitumor agents  
Cardiovascular agents  
Contraceptives  
Tuberculostatics  
(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)

IT Biliary tract, disease  
(primary biliary cirrhosis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (proteinuria; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Fibrosis  
Sarcoidosis  
(pulmonary; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Injury  
(reperfusion; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Bone  
(resorption; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Lung, disease  
(sarcoidosis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Shock (circulatory collapse)  
(septic; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Inflammation  
(systemic inflammatory response syndrome; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Lupus erythematosus  
(systemic; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Disease, animal  
(temporomandibular joint; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Joint, anatomical  
(temporomandibular, disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Osteoporosis  
(therapeutic agents, postmenopausal; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)
- IT Shock (circulatory collapse)  
(toxic shock syndrome; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Digestive tract, disease  
(ulcer, peptic, Helicobacter pylori infection during; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Inflammation  
Intestine, disease  
(ulcerative colitis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT 165245-96-5, p38 Kinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; preparation of heteroaryl ureas containing nitrogen hetero-atoms as)
- IT 673-09-6P, 4-(4-Pyridylthio)aniline 6337-24-2P, 1-Methoxy-4-(4-nitrophenoxy)benzene 13472-85-0P, 5-Bromo-2-methoxypyridine 18994-90-6P, 4-(1-Imidazolylmethyl)-1-nitrobenzene 27237-21-4P, 4-(3-Carboxyphenoxy)-1-nitrobenzene 27692-74-6P, 4-(4-Pyridinylmethyl)aniline 28232-34-0P, 5-Nitro-2-(4-methylphenoxy)pyridine 28232-52-2P, 3-(3-Pyridinyloxy)-1-nitrobenzene 29264-35-5P, 4-(3-Carboxy-4-hydroxyphenoxy)-1-nitrobenzene 31465-36-8P, 4-(4-Methoxyphenoxy)aniline 32361-76-5P, 3-(4-Nitrobenzyl)pyridine 36089-89-1P, 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene 50727-06-5P, 5-Hydroxyisoindoline-1,3-dione 51727-15-2P, 4-Chloropyridine-2-carbonyl chloride hydrochloride 51834-97-0P, 5-Hydroxy-2-methoxypyridine 56643-85-7P, 4-(1-Imidazolylmethyl)aniline 62248-47-9P, 4-[(4-Butoxyphenyl)thio]-1-nitrobenzene 62248-51-5P, 4-(4-Butoxyphenyl)thioaniline 64064-63-7P, 4-(6-Methyl-3-pyridinyloxy)-1-nitrobenzene 70991-08-1P, 4-(2-Pyridinylthio)aniline 71708-64-0P, 4-[3-(N-Methylcarbamoyl)phenoxy]-1-nitrobenzene 85666-15-5P, 4-[(3-Pyridinyl)methyl]aniline 92575-23-0P, 3-(4-Pyridinylthio)aniline 99586-65-9P, 4-Chloro-2-pyridinecarboxamide 102877-78-1P 116289-71-5P,

3-(3-Pyridinyloxy)aniline 135680-03-4P, 4-(4-tert-Butoxycarbonylamino)benzyl aniline 176977-85-8P, Methyl 4-chloropyridine-2-carboxylate hydrochloride 178809-75-1P, 4-[Hydroxy(4-pyridyl)methyl]-1-nitrobenzene 220000-87-3P 228401-26-1P, 3-(Trifluoromethyl)-4-(4-pyridinylthio)nitrobenzene 228401-27-2P, 3-(Trifluoromethyl)-4-(4-pyridinylthio)aniline 228401-28-3P, 4-[(4-Phenyl-2-thiazolyl)thio]-1-nitrobenzene 228401-29-4P, 4-[(4-Phenyl-2-thiazolyl)thio]aniline 228401-31-8P, 4-(6-Methyl-3-pyridinyloxy)aniline 228401-32-9P, 4-(3,4-Dimethoxyphenoxy)-1-nitrobenzene 228401-33-0P, 4-(3,4-Dimethoxyphenoxy)aniline 228401-34-1P, 3-(6-Methyl-3-pyridinyloxy)-1-nitrobenzene 228401-35-2P, 3-(6-Methyl-3-pyridinyloxy)aniline 228401-36-3P, 5-Amino-2-(4-methylphenoxy)pyridine Dihydrochloride 228401-37-4P, 4-(3-Thienylthio)-1-nitrobenzene 228401-38-5P, 4-(5-Pyrimidinylthio)aniline 228401-39-6P, 4-[(2-Methoxy-5-pyridyl)oxy]-1-nitrobenzene 228401-40-9P, 4-(2-Methyl-4-pyridinyloxy)aniline 228401-41-0P, Methyl(4-nitrophenyl)(4-pyridyl)amine 228401-43-2P, 4-(3-Methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene 228401-44-3P, 4-(3-Carboxy-4-methoxyphenoxy)-1-nitrobenzene 284462-37-9P, 4-[2-(N-Methylcarbamoyl)-4-pyridyloxy]aniline 284462-38-0P, 5-(4-Nitrophenoxy)isoindoline-1,3-dione 284462-39-1P, 5-(4-Aminophenoxy)isoindoline-1,3-dione 284462-46-0P, 4-[3-(N-Methylcarbamoyl)-4-methoxyphenoxy]-1-nitrobenzene 284462-47-1P, 4-[3-(N-Methylcarbamoyl)-4-methoxyphenoxy]aniline 284462-55-1P, 4-(3-Ethoxycarbonylphenoxy)-1-nitrobenzene 284462-56-2P, 4-(3-N-Methylcarbamoylphenoxy)aniline 284462-78-8P, 3-[2-(N-Methylcarbamoyl)-4-pyridyloxy]aniline 284462-79-9P, 3-(2-Carbamoyl-4-pyridyloxy)aniline 284462-80-2P, 4-(2-Carbamoyl-4-pyridyloxy)aniline 284462-84-6P, 4-(4-Methylsulfonylphenoxy)aniline 432050-13-0P, 4-(3-Thienylthio)aniline 432050-14-1P, 4-[(2-Methoxy-5-pyridyl)oxy]aniline 432050-15-2P, Methyl(4-aminophenyl)(4-pyridyl)amine 432050-16-3P, 4-[Hydroxy(4-pyridyl)methyl]aniline

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)

IT 284461-54-7P, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(1,3-dioxoisindolin-5-yloxy)phenyl]urea 284670-98-0P, N,N'-Bis[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 432050-17-4P 432050-18-5P 432050-19-6P, N,N'-Bis(2-methoxy-3-quinolyl)urea 432050-20-9P 432050-21-0P, N-[5-Trifluoromethyl-2-pyridyl]-N'-[3-(4-pyridylthio)phenyl]urea 432050-22-1P, N-(2-Methoxy-3-quinolyl)-N'-[4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)phenyl]urea 432050-23-2P, N-(2-Methoxy-3-quinolyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea 432050-24-3P, N-(2-Methoxy-3-quinolyl)-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 432050-25-4P, N-(2-Methoxy-3-quinolyl)-N'-[3-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 432050-26-5P, N-(2-Methoxy-3-quinolyl)-N'-[3-(2-carbamoyl-4-pyridyloxy)phenyl]urea 432050-27-6P, N-(2-Methoxy-3-quinolyl)-N'-[4-[3-(N-isopropylcarbamoyl)phenoxy]phenyl]urea 432050-28-7P, N-(2-Methoxy-3-quinolyl)-N'-[4-[4-methoxy-3-(N-methylcarbamoyl)phenoxy]phenyl]urea 432050-29-8P, N-(3-Isoquinolyl)-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 432050-30-1P, N-(4-tert-Butyl-2-pyridinyl)-N'-(4-methylphenyl)urea 432050-31-2P, N-(4-tert-Butyl-2-pyridinyl)-N'-(4-fluorophenyl)urea 432050-32-3P, N-(4-tert-Butyl-2-pyridinyl)-N'-(1-naphthyl)urea 432050-33-4P, N-(4-tert-Butyl-2-pyridinyl)-N'-[4-(4-methoxyphenoxy)phenyl]urea 432050-34-5P, N-(5-Trifluoromethyl-2-pyridinyl)-N'-[4-(4-pyridylmethyl)phenyl]urea 432050-35-6P, N-(3-Isoquinolyl)-N'-(4-methylphenyl)urea 432050-36-7P, N-(3-Isoquinolyl)-N'-(4-fluorophenyl)urea 432050-37-8P, N-(3-Isoquinolyl)-N'-(2,3-dichlorophenyl)urea 432050-38-9P, N-(3-Isoquinolyl)-N'-(1-naphthyl)urea 432050-39-0P, N-(3-Isoquinolyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea 432050-40-3P, N-(3-Quinolyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea 432050-41-4P, N-(4-tert-Butyl-2-pyridyl)-N'-(4-(4-methylphenoxy)phenyl)urea 432050-42-5P, N-(4-tert-Butyl-2-pyridyl)-N'-(4-

(4-pyridyloxy)phenyl)urea 432050-43-6P, N-(4-tert-Butyl-2-pyridyl)-N'-(4-(4-pyridinylthio)phenyl)urea 432050-44-7P, N-(4-tert-Butyl-2-pyridyl)-N'-(3-(4-pyridinylthio)phenyl)urea 432050-45-8P 432050-46-9P  
 432050-47-0P 432050-48-1P 432050-49-2P 432050-50-5P 432050-51-6P,  
 N-(1-(4-Methyl-1-piperazinyl)isoquinol-3-yl)-N'-(4-(4-pyridyl)methyl)phenyl)urea 432050-52-7P, N-(Isoquinol-3-yl)-N'-(4-(3-(methylcarbamoyl)phenoxy)phenyl)urea 432050-53-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)

IT 75-31-0, Isopropylamine, reactions 86-84-0, 1-Naphthyl isocyanate 98-98-6, Picolinic acid 100-11-8, 4-Nitrobenzyl bromide 100-15-2, N-Methyl-4-nitroaniline 101-77-9, 4,4'-Methylenedianiline 101-79-1, 4-(4-Chlorophenoxy)aniline 106-44-5, 4-Methylphenol, reactions 109-00-2, 3-Hydroxypyridine 123-30-8, 4-Aminophenol 139-59-3, 4-Phenoxyaniline 150-76-5, 4-Methoxyphenol 288-32-4, Imidazole, reactions 350-46-9, 1-Fluoro-4-nitrobenzene 400-74-8, 2-Fluoro-5-nitrobenzotrifluoride 580-17-6, 3-Aminoquinoline 585-79-5, 1-Bromo-3-nitrobenzene 591-27-5, 3-Aminophenol 610-35-5, 4-Hydroxyphthalic acid 620-95-1, 3-Benzylpyridine 622-58-2, 4-Tolyl isocyanate 624-28-2, 2,5-Dibromopyridine 626-61-9, 4-Chloropyridine 626-64-2, 4-Hydroxypyridine 872-31-1, 3-Bromothiophene 1083-48-3, 4-(4-Nitrobenzyl)pyridine 1121-78-4, 5-Hydroxy-2-methylpyridine 1193-02-8, 4-Aminothiophenol 1195-45-5, 4-Fluorophenyl isocyanate 1849-36-1, 4-Nitrothiophenol 2033-89-8, 3,4-Dimethoxyphenol 2103-88-0, 2-Mercapto-4-phenylthiazole 3678-63-5, 4-Chloro-2-methylpyridine 4548-45-2, 2-Chloro-5-nitropyridine 4556-23-4, 4-Mercaptopyridine 4595-59-9, 5-Bromopyrimidine 7379-35-3, 4-Chloropyridine hydrochloride 7781-98-8, Ethyl 3-hydroxybenzoate 16588-75-3, 2-Methoxy-5-(trifluoromethyl)phenyl isocyanate 21101-60-0, 4-(4-Nitrophenylthio)phenol 22948-02-3, 3-Aminothiophenol 24424-99-5, Di-tert-butyl dicarbonate 25267-27-0, Iodobutane 25475-67-6, 3-Aminoisoquinoline 27163-00-4, 4-[(4-Methoxyphenyl)methylamino]aniline 33252-26-5, 2-Amino-4-tert-butylpyridine 36265-31-3, 4-(4-Methylthiophenoxy)-1-nitrobenzene 41195-90-8, 2,3-Dichlorophenyl isocyanate 41295-20-9, 4-(4-Methylphenoxy)aniline 53750-66-6, 4-Chloropyridine-2-carbonyl chloride 73322-01-7, 4-(2-Pyridinylthio)-1-nitrobenzene 74784-70-6, 2-Amino-5-(trifluoromethyl)pyridine 150009-83-9, 3-Amino-2-methoxyquinoline 170893-64-8, 4-(4-Pyridylcarbonyl)aniline 362688-26-4, 1-(4-Methylpiperazinyl)-3-aminoisoquinoline  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)

=> b wpix

FILE 'WPIX' ENTERED AT 09:22:19 ON 06 JUN 2005  
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 3 JUN 2005 <20050603/UP>  
 MOST RECENT DERWENT UPDATE: 200535 <200535/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
 PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
 GUIDES, PLEASE VISIT:

<http://thomsonderwent.com/support/userguides/>

&lt;&lt;&lt;

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
FIRST VIEW - FILE WPIFV.  
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
PLEASE CHECK:  
<http://thomsonderwent.com/support/dwpieref/reftools/classification/code-revision/>  
FOR DETAILS. <<<

=> d all 14

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-499051 [44] WPIX

CR 2000-499086 [44]; 2002-627516 [67]; 2003-067622 [06]

DNC C2000-149713

TI Method of treating a disease mediated by p38 kinase within a host  
comprises administration of urea derivatives e.g. for the treatment of  
cancer or arthritis.

DC B05

IN DUMAS, J; KHIRE, U; LOWINGER, T B; MONAHAN, M; NATERO, R; RENICK, J;  
RIEDL, B; SCOTT, W J; SIBLEY, R N; SMITH, R A; WOOD, J E; GUNN, D E;  
HATOUM-MOKDAD, H; NAERO, R; WILLIAM, S J

PA (FARB) BAYER CORP; (DUMA-I) DUMAS J; (KHIR-I) KHIRE U; (LOWI-I) LOWINGER T  
B; (MONA-I) MONAHAN M; (NAER-I) NAERO R; (RENI-I) RENICK J; (RIED-I) RIEDL  
B; (SIBL-I) SIBLEY R N; (SMIT-I) SMITH R A; (WILL-I) WILLIAM S J; (WOOD-I)  
WOOD J E; (SCOT-I) SCOTT W J

CYC 91

PI WO 2000041698 A1 20000720 (200044)\* EN 148 A61K031-535  
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
OA PT SD SE SL SZ TZ UG ZW  
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES  
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS  
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL  
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000027250 A 20000801 (200054) A61K031-535

EP 1158985 A1 20011205 (200203) EN A61K031-535

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
RO SE SI

US 2002065296 A1 20020530 (200240) A61K031-506 <--

MX 2001007120 A1 20011101 (200279) A61K031-17

JP 2002534468 W 20021015 (200282) 165 A61K031-17

US 2003105091 A1 20030605 (200339) A61K031-54

US 2003139605 A1 20030724 (200352) C07D213-63

AU 2004200566 A1 20040311 (200459)# A61K031-535

ADT WO 2000041698 A1 WO 2000-US768 20000113; AU 2000027250 A AU 2000-27250  
20000113; EP 1158985 A1 EP 2000-905597 20000113, WO 2000-US768 20000113;  
US 2002065296 A1 Provisional US 1999-115878P 19990113, Cont of US  
1999-257265 19990225, CIP of US 1999-425229 19991022, CIP of US  
2001-778039 20010207, US 2001-838286 20010420; MX 2001007120 A1 MX  
2001-7120 20010712; JP 2002534468 W JP 2000-593309 20000113, WO 2000-US768  
20000113; US 2003105091 A1 Provisional US 1999-115878P 19990113, CIP of US  
1999-257265 19990225, Cont of US 1999-425229 19991022, US 2002-86417  
20020304; US 2003139605 A1 Provisional US 1999-115877P 19990113,  
Provisional US 1999-115878P 19990113, CIP of US 1999-257266 19990225, Cont  
of US 1999-425228 19991022, Cont of US 2001-948915 20010910, US 2002-71248  
20020211; AU 2004200566 A1 Div ex AU 2000-27250 20000113, AU 2004-200566  
20040213

FDT AU 2000027250 A Based on WO 2000041698; EP 1158985 A1 Based on WO  
2000041698; JP 2002534468 W Based on WO 2000041698

PRAI US 1999-425229 19991022; US 1999-115878P 19990113;  
US 1999-257265 19990225; US 2001-778039 20010207;  
US 2001-838286 20010420; US 2002-86417 20020304;

US 1999-115877P 19990113; US 1999-257266 19990225;  
 US 1999-425228 19991022; US 2001-948915 20010910;  
 US 2002-71248 20020211; AU 2004-200566 20040213

IC ICM A61K031-17; A61K031-506; A61K031-535; A61K031-54; C07D213-63  
 ICS A61K031-34; A61K031-40; A61K031-4035; A61K031-44; A61K031-445;  
 A61K031-4709; A61K031-4725; A61K031-495; A61K031-497; A61K031-50;  
 A61K031-501; C07D213-70; C07D295-12; C07D295-18

ICA C07C275-36; C07D207-09; C07D209-46; C07D209-48; C07D213-64; C07D213-75;  
 C07D213-81; C07D307-14; C07D401-12

AB WO 200041698 A UPAB: 20040915

NOVELTY - Method of treating a disease mediated by p38 kinase within a host comprises administration of urea derivatives (I) or their salts.

DETAILED DESCRIPTION - Method of treating a disease mediated by p38 kinase within a host comprises administration of urea derivatives of formula (I) or their salts.

D' = NHC(O)NH;

A = L-(M-L1)q which contains up to 40 carbon atoms;  
 L = 5-6 membered cyclic structure bound to D' containing 0-4 O, N and S, optionally substituted by Y';  
 L1 = at least 5 membered cyclic group containing 0-4 O, N and S, optionally substituted by L' or Y';  
 M = bridging group of at least one atom;  
 q = 1-3;  
 B' = mono-, di or tricyclic aryl or heteroaryl group which contains up to 30 carbon atoms with at least one 6-membered cyclic group containing 0-4 N, O and S bound directly to D' all optionally substituted by Y';  
 L' = SO2Rx, C(O)Rx, C(NRy)Rz;  
 Ry = H or R';  
 R' = a group containing up to 24 carbon atoms, optionally containing N, S and O optionally substituted by halo;  
 Rz = H or a group containing up to 30 carbon atoms, optionally containing N, S and O and optionally substituted by halo, OH or R';  
 Rx = Rz or NRaRb;  
 Ra, Rb = H, a group containing up to 30 carbon atoms, optionally containing N, S and O and optionally substituted by halo, OH or R', or OSi(Rf)3;  
 Rf = H or a group containing up to 30 carbon atoms, optionally containing N, S and O and optionally substituted by halo, OH or R'; or  
 Ra + Rb = 5-7 membered heterocycle containing 1-3 N, S and O, optionally substituted by halo, OH or R'; or  
 Ra or Rb = C(O) or 1-5C alkylene (optionally substituted with halo, OH or R') bound to L to form an at least 5 membered cyclic structure;  
 Y' = halo or (W')n;  
 n = 0-3;  
 W' = CN, C(O)OR7, C(O)NR7R7, NO2 C(O)R7, OR7, SR7, NR7R7, NR7C(O)OR7, Q-Ar' or a group containing up to 24 carbon atoms, optionally containing N, S and O and optionally substituted by CN, C(O)OR7, C(O)NR7R7, C(O)R7, OR7, SR7, NR7R7, NO2, NR7C(O)R7, NR7C(O)OR7 or halo;  
 R7 = H or R';  
 Q = O, S, N(R7), (CH2)m, C(O), CH(OH), (CH2)mO, (CH2)mS, (CH2)mN(R7), O(CH2)m, CHXa, CH(Xa)2, S(CH2)m and NR7(CH2)m;  
 m = 1-3;  
 Xa = halo;  
 Ar' = 5-6 membered aromatic containing 0-2 N, O, S optionally substituted by halo or (Z')n; and  
 Z' = CN, C(O)OR7, C(O)NR7R7, NO2, OR7, SR7, NR7R7, NR7C(O)OR7 or a group containing up to 24 carbon atoms, optionally containing N, S and O and optionally substituted by CN, C(O)OR7, C(O)NR7R7, C(O)R7, OR7, SR7, NR7R7, NO2, NR7C(O)R7 or NR7C(O)OR7.

ACTIVITY - Cytostatic; osteopathic; antiarthritic; antirheumatic; antibacterial; immunosuppressive; antiarteriosclerotic; neuroprotective; antiinflammatory; gastrointestinal; respiratory; hepatotropic; protozoacide; antidiabetic; cerebroprotective; vulnerary, radioprotective; dermatological.

MECHANISM OF ACTION - P38 kinase inhibitor; tumor necrosis factor alpha (TNF alpha) inhibitor; matrix-destroying metalloprotease (MMP)

inhibitor.

No compound specific biological data given. P38 kinase inhibitory activity was determined using recombinant human p38 (0.5  $\mu$ g/ml) mixed with a substrate of myelin basic protein (5  $\mu$ g/ml) in kinase buffer and <sup>32</sup>P-labeled ATP. The amount of radioactivity incorporated into the substrate was measured. (I) showed p38 IC<sub>50</sub> values of 1 nM - 10  $\mu$ M.

USE - (I) are used in the treatment of cancerous growth mediated by p38 kinase and in the treatment of rheumatoid arthritis, osteoarthritis, septic arthritis, tumor metastasis, periodontal disease, corneal ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurysmal aortic birth control, dystrophic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by matrix-destroying metalloproteinase (MMP) activity, temporomandibular joint disease, demyelinating disease of the nervous system, rheumatic fever, bone reabsorption, postmenopausal osteoporosis, sepsis, gram negative sepsis, septic shock, systemic inflammatory response syndrome, inflammatory bowel syndrome, inflammatory bowel disease, Jarisch-Herxheimer reaction, asthma, adult respiratory distress syndrome, acute pulmonary fibrotic disease, pulmonary sarcoidosis, allergic respiratory disease, silicosis, alveolar injury, hepatic failure, liver disease during acute inflammation, severe alcoholic hepatitis, malaria, non-insulin-dependant diabetes mellitus (NIDDM), congestive heart failure, atherosclerosis, Alzheimer's disease, acute encephalitis, brain injury, multiple sclerosis, lymphoid malignancy, pancreatitis, impaired wound healing in infection, inflammation and cancer, myelodysplastic syndrome, systemic lupus erythematosus, biliary cirrhosis, bowel necrosis, psoriasis, radiation injury/toxicity following administration of monoclonal antibodies, host-versus-graft reaction, lung allograft rejection or complications following hip replacement (claimed).

ADVANTAGE - Unlike prior art compositions for treating osteoarthritis, rheumatoid arthritis and septic arthritis p38 kinase inhibitors halt or reverse the progression of cartilage loss and remove or delay the need for surgical intervention. (I) are less toxic than prior art p38 kinase inhibitors.

Dwg.0/0

FS CPI


FA AB; GI; DCN

MC CPI: B06-H; B07-H; B10-A13D; B14-A01; B14-A03B; B14-C03; B14-C09;  
B14-D07C; B14-E10; B14-F07; B14-F10; B14-G02; B14-H01; B14-J01A;  
B14-J01B; B14-K01A; B14-K01B; B14-L06; B14-N17A; B14-N17B; B14-N17C;  
B14-S04


=> b home

FILE 'HOME' ENTERED AT 09:22:26 ON 06 JUN 2005

=>



1-(4-(3-(ethylcarbamoyl)-4-methoxyphenoxy)phenyl)-3-(2-methoxyquinolin-3-yl)urea



=> b reg

FILE 'REGISTRY' ENTERED AT 11:41:14 ON 06 JUN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6  
DICTIONARY FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide l55 tot

L55 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 774552-58-8 REGISTRY  
ED Entered STN: 04 Nov 2004  
CN Urea, N-(4-methylphenyl)-N'-3-quinolinyl- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C17 H15 N3 O  
SR Chemical Library  
Supplier: Scientific Exchange, Inc.  
LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L55 ANSWER 2 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-40-3 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN Urea, N-[4-(4-pyridinylmethyl)phenyl]-N'-3-quinolinyl- (9CI)  
(CA INDEX NAME)  
OTHER NAMES:  
CN N-(3-Quinolinyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea  
FS 3D CONCORD

Search done by Noble Jarrell

MF C22 H18 N4 O  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 3 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 432050-39-0 REGISTRY  
 ED Entered STN: 19 Jun 2002  
 CN Urea, N-3-isoquinolinyl-N'-[4-(4-pyridinylmethyl)phenyl]- (9CI)  
 (CA INDEX NAME)

OTHER NAMES:

CN N-(3-Isoquinolyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea  
 FS 3D CONCORD  
 MF C22 H18 N4 O  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 4 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 432050-38-9 REGISTRY  
 ED Entered STN: 19 Jun 2002  
 CN Urea, N-3-isoquinolinyl-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN N-(3-Isoquinolyl)-N'-(1-naphthyl)urea  
 FS 3D CONCORD  
 MF C20 H15 N3 O  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L55 ANSWER 5 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-37-8 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN Urea, N-(2,3-dichlorophenyl)-N'-3-isoquinolyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN N-(3-Isoquinolyl)-N'-(2,3-dichlorophenyl)urea  
FS 3D CONCORD  
MF C16 H11 Cl2 N3 O  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L55 ANSWER 6 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-36-7 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN Urea, N-(4-fluorophenyl)-N'-3-isoquinolyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN N-(3-Isoquinolyl)-N'-(4-fluorophenyl)urea  
FS 3D CONCORD  
MF C16 H12 F N3 O  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L55 ANSWER 7 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-35-6 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN Urea, N-3-isoquinoliny1-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN N-(3-Isoquinolyl)-N'-(4-methylphenyl)urea  
FS 3D CONCORD  
MF C17 H15 N3 O  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 8 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-33-4 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN Urea, N-[4-(1,1-dimethylethyl)-2-pyridinyl]-N'-[4-(4-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN N-(4-tert-Butyl-2-pyridinyl)-N'-[4-(4-methoxyphenoxy)phenyl]urea  
FS 3D CONCORD  
MF C23 H25 N3 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 9 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-32-3 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN Urea, N-[4-(1,1-dimethylethyl)-2-pyridinyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN N-(4-tert-Butyl-2-pyridinyl)-N'-(1-naphthyl)urea  
FS 3D CONCORD


MF C20 H21 N3 O  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 10 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 432050-31-2 REGISTRY  
 ED Entered STN: 19 Jun 2002  
 CN Urea, N-[4-(1,1-dimethylethyl)-2-pyridinyl]-N'-(4-fluorophenyl)-  
 (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN N-(4-tert-Butyl-2-pyridinyl)-N'-(4-fluorophenyl)urea  
 FS 3D CONCORD  
 MF C16 H18 F N3 O  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 11 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 432050-30-1 REGISTRY  
 ED Entered STN: 19 Jun 2002  
 CN Urea, N-[4-(1,1-dimethylethyl)-2-pyridinyl]-N'-(4-methylphenyl)-  
 (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN N-(4-tert-Butyl-2-pyridinyl)-N'-(4-methylphenyl)urea  
 FS 3D CONCORD  
 MF C17 H21 N3 O  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Search done by Noble Jarrell



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 12 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN

RN 432050-29-8 REGISTRY

ED Entered STN: 19 Jun 2002

CN 2-Pyridinecarboxamide, 4-[4-[[[(3-isoquinolinylamino)carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN N-(3-Isoquinolyl)-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea

FS 3D CONCORD

MF C23 H19 N5 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 13 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN

RN 432050-27-6 REGISTRY

ED Entered STN: 19 Jun 2002

CN Benzamide, 3-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN N-(2-Methoxy-3-quinolyl)-N'-[4-[3-(N-isopropylcarbamoyl)phenoxy]phenyl]urea

FS 3D CONCORD

MF C27 H26 N4 O4

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L55 ANSWER 14 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-26-5 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN 2-Pyridinecarboxamide, 4-[3-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN N-(2-Methoxy-3-quinolyl)-N'-[3-(2-carbamoyl-4-pyridyloxy)phenyl]urea  
FS 3D CONCORD  
MF C23 H19 N5 O4  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 15 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-25-4 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN 2-Pyridinecarboxamide, 4-[3-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN N-(2-Methoxy-3-quinolyl)-N'-[3-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea  
FS 3D CONCORD  
MF C24 H21 N5 O4  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 16 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-24-3 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-

quinolinyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN N-(2-Methoxy-3-quinolyl)-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea  
 FS 3D CONCORD  
 MF C23 H19 N5 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1907 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 17 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 432050-23-2 REGISTRY  
 ED Entered STN: 19 Jun 2002  
 CN Benzamide, 3-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN N-(2-Methoxy-3-quinolyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea  
 FS 3D CONCORD  
 MF C25 H22 N4 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 18 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 432050-22-1 REGISTRY  
 ED Entered STN: 19 Jun 2002  
 CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN N-(2-Methoxy-3-quinolinyl)-N'-[4-(2-(N-Methylcarbamyl)-4-pyridyloxy)phenyl]urea  
 FS 3D CONCORD  
 MF C24 H21 N5 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 19 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 432050-17-4 REGISTRY  
ED Entered STN: 19 Jun 2002  
CN Urea, N-(2,3-dichlorophenyl)-N'-[4-(1,1-dimethylethyl)-2-pyridinyl]-  
(9CI) (CA INDEX NAME)

OTHER NAMES:


CN N-(4-tert-Butylpyridyl)-N'-(2,3-dichlorophenyl)urea  
FS 3D CONCORD  
MF C16 H17 Cl2 N3 O  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L55 ANSWER 20 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 413613-26-0 REGISTRY  
ED Entered STN: 12 May 2002  
CN Urea, N-1-naphthalenyl-N'-3-quinolinyl- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C20 H15 N3 O  
SR Chemical Library  
Supplier: ChemBridge Corporation  
LC STN Files: CHEMCATS




## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L55 ANSWER 21 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 309284-04-6 REGISTRY  
ED Entered STN: 18 Dec 2000  
CN Urea, N-(4-fluorophenyl)-N'-3-quinolinyl- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C16 H12 F N3 O  
SR Chemical Library  
Supplier: ChemDiv, Inc.  
LC STN Files: CHEMCATS



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L55 ANSWER 22 OF 22 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 304510-28-9 REGISTRY  
ED Entered STN: 27 Nov 2000  
CN Urea, N-4-isoquinolinyl-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C20 H15 N3 O  
SR Chemical Library  
Supplier: AsInEx  
LC STN Files: CHEMCATS



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> d his full

(FILE 'HOME' ENTERED AT 09:19:30 ON 06 JUN 2005)

FILE 'HCAPLUS' ENTERED AT 09:19:43 ON 06 JUN 2005  
L1 1 SEA ABB=ON PLU=ON US20020065296/PN OR US99-115878/AP,PRN

FILE 'REGISTRY' ENTERED AT 09:20:28 ON 06 JUN 2005

FILE 'HCAPLUS' ENTERED AT 09:20:29 ON 06 JUN 2005  
L2 TRA L1 1- RN : 157 TERMS

FILE 'REGISTRY' ENTERED AT 09:20:30 ON 06 JUN 2005

Search done by Noble Jarrell

L3 157 SEA ABB=ON PLU=ON L2

FILE 'WPIX' ENTERED AT 09:20:35 ON 06 JUN 2005

L4 1 SEA ABB=ON PLU=ON US20020065296/PN OR US99-115878/AP,PRN

FILE 'REGISTRY' ENTERED AT 10:09:52 ON 06 JUN 2005

L5 78 SEA ABB=ON PLU=ON L3 AND NC5/ES

L6 13 SEA ABB=ON PLU=ON L5 AND NC5-C6/ES

L7 5 SEA ABB=ON PLU=ON L3 AND NR=4 AND 2 46.150.18/RID AND NC5-C6/ES

L8 0 SEA ABB=ON PLU=ON L3 AND N(1A)ETHYL

L9 QUE ABB=ON PLU=ON (PMS OR MAN OR IDS)/CI OR COMPD OR COMPOUND OR UNSPECIFIED OR (D OR T)/ELS

L10 458 SEA ABB=ON PLU=ON C17H21N3O AND NR=2

L11 106 SEA ABB=ON PLU=ON L10 AND NC5/ES AND 46.150.18/RID

L12 103 SEA ABB=ON PLU=ON L11 NOT L9

L13 7 SEA ABB=ON PLU=ON L12 AND DIMETHYLETHYL  
SEL RN 2 L13

L14 1 SEA ABB=ON PLU=ON 432050-30-1/BI AND L13

L15 9 SEA ABB=ON PLU=ON C16H18FN3O AND NR=2 AND NC5/ES AND 46.150.18/RID

L16 1 SEA ABB=ON PLU=ON L15 AND UREA

L17 12 SEA ABB=ON PLU=ON C16H17CL2N3O AND NR=2 AND NC5/ES AND 46.150.18/RID

L18 1 SEA ABB=ON PLU=ON L17 AND UREA

L19 3 SEA ABB=ON PLU=ON L3 AND C6-C6/ES

L20 111 SEA ABB=ON PLU=ON C20H21N3O AND NR=3 AND NC5/ES

L21 3 SEA ABB=ON PLU=ON L20 AND C6-C6/ES

L22 1 SEA ABB=ON PLU=ON 432050-32-3/BI AND L21

L23 488 SEA ABB=ON PLU=ON C23H25N3O3 AND NR=3

L24 81 SEA ABB=ON PLU=ON L23 AND NC5/ES AND 2 46.150.18/RID

L25 81 SEA ABB=ON PLU=ON L24 NOT L9

L26 5 SEA ABB=ON PLU=ON L25 AND UREA AND METHOXYPHEN?  
SEL RN 3 L26

L27 1 SEA ABB=ON PLU=ON 432050-33-4/BI AND L26

L28 1392 SEA ABB=ON PLU=ON C17H15N3O NOT L9

L29 124 SEA ABB=ON PLU=ON L28 AND NR=3 AND NC5-C6/ES AND 46.150.18/RID  
D

L30 20 SEA ABB=ON PLU=ON L29 AND UREA  
D STR TOT  
SEL RN L30 1 10

L31 2 SEA ABB=ON PLU=ON (432050-35-6/BI OR 774552-58-8/BI) AND L30

L32 12 SEA ABB=ON PLU=ON C16H12FN3O AND NR=3 AND NC5-C6/ES AND 46.150.18/RID  
SEL RN 4 8 L32

L33 2 SEA ABB=ON PLU=ON (309284-04-6/BI OR 432050-36-7/BI) AND L32

L34 24 SEA ABB=ON PLU=ON C16H11CL2N3O AND NC5-C6/ES AND 46.150.18/RID  
D  
SEL RN L34 10

L35 1 SEA ABB=ON PLU=ON 432050-37-8/BI AND L34

L36 17 SEA ABB=ON PLU=ON C20H15N3O AND C6-C6/ES AND NC5-C6/ES AND NR=4  
D STR TOT  
SEL RN 2 4 5 L36

L37 3 SEA ABB=ON PLU=ON (304510-28-9/BI OR 413613-26-0/BI OR 432050-38-9/BI) AND L36

L38 23 SEA ABB=ON PLU=ON C22H18N4O AND NR=4 AND NC5-C6/ES AND NC5/ES AND 46.150.18/RID  
D SCA

L39 2 SEA ABB=ON PLU=ON L38 AND UREA AND PYRIDINYLMETHYL  
D SCA  
D COS

L40 1130 SEA ABB=ON PLU=ON (C25H22N4O4 OR C24H21N5O4 OR C24H21N5O4 OR C24H21N5O4 OR C23H19N5O4 OR C27H26N4O4 OR C27H26N4O5 OR C23H19N5O3) AND NR=4 NOT L9

L41 60 SEA ABB=ON PLU=ON L40 AND NC5-C6/ES AND (2 46.150.18/RID OR

NC5/ES AND 46.150.18/RID)  
 SEL RN L41 33 29 30  
 L42 3 SEA ABB=ON PLU=ON (432050-24-3/BI OR 432050-27-6/BI OR  
 432050-29-8/BI) AND L41  
 L43 8 SEA ABB=ON PLU=ON C25H22N4O4 AND 2 46.150.18/RID AND  
 NC5-C6/ES  
 D SCA  
 L44 1 SEA ABB=ON PLU=ON L43 AND BENZAMIDE  
 L45 4 SEA ABB=ON PLU=ON C24H21N5O4 AND NR=4 AND NC5-C6/ES AND  
 46.150.18/RID AND NC5/ES  
 L46 2 SEA ABB=ON PLU=ON L45 AND PYRIDINECARBOXAMIDE  
 L47 4 SEA ABB=ON PLU=ON C24H21N5O4 AND NC5-C6/ES AND NC5/ES AND  
 46.150.18/RID  
 L48 12 SEA ABB=ON PLU=ON L3 AND NC5-C6/ES AND NC5/ES AND 46.150.18/R  
 ID AND NR=4  
 L49 3 SEA ABB=ON PLU=ON C23H19N5O4 AND NR=4 AND NC5-C6/ES AND  
 NC5/ES AND 46.150.18/RID  
 L50 2 SEA ABB=ON PLU=ON L49 AND PYRIDINECARBOXAMIDE  
 L51 9 SEA ABB=ON PLU=ON C27H26N4O5 AND NR=4 AND 2 46.150.18/RID  
 AND NC5-C6/ES  
 L52 262 SEA ABB=ON PLU=ON C23H19N5O3  
 L53 6 SEA ABB=ON PLU=ON L52 AND NR=4 AND NC5/ES AND NC5-C6/ES AND  
 46.150.18/RID  
 L54 1 SEA ABB=ON PLU=ON L53 AND PYRIDINECARBOXAMIDE  
 L55 22 SEA ABB=ON PLU=ON L14 OR L16 OR L18 OR L22 OR L27 OR L31 OR  
 L33 OR L35 OR L37 OR L39 OR L42 OR L44 OR L46 OR L50 OR L54

FILE 'HCAPLUS' ENTERED AT 11:42:46 ON 06 JUN 2005

L56 6 SEA ABB=ON PLU=ON L55

FILE 'HCAOLD' ENTERED AT 11:43:28 ON 06 JUN 2005

L57 0 SEA ABB=ON PLU=ON L55

FILE 'HCAPLUS' ENTERED AT 11:53:12 ON 06 JUN 2005

E DUMAS J/AU  
 L58 427 SEA ABB=ON PLU=ON ("DUMAS J"/AU OR "DUMAS J B"/AU OR "DUMAS  
 J C"/AU OR "DUMAS J F"/AU OR "DUMAS J G"/AU OR "DUMAS J I"/AU  
 OR "DUMAS J J"/AU OR "DUMAS J L"/AU OR "DUMAS J M"/AU OR  
 "DUMAS J P"/AU OR "DUMAS J R"/AU OR "DUMAS J R DEGORCE"/AU)  
 E DUMAS JACQUES/AU  
 L59 104 SEA ABB=ON PLU=ON ("DUMAS JACQUES"/AU OR "DUMAS JACQUES  
 P"/AU)  
 E RIEDL B/AU  
 L60 170 SEA ABB=ON PLU=ON ("RIEDL B"/AU OR "RIEDL BAUCH VACLAV"/AU  
 OR "RIEDL BERNARD"/AU OR "RIEDL BERNARD Y"/AU OR "RIEDL  
 BERND"/AU)  
 E KHIRE U/AU  
 L61 43 SEA ABB=ON PLU=ON ("KHIRE U R"/AU OR "KHIRE UDAY"/AU OR  
 "KHIRE UDAY R"/AU)  
 E MOKDAD H/AU  
 L62 1 SEA ABB=ON PLU=ON "MOKDAD H"/AU  
 E HATOUM MOKDAD/AU  
 L63 28 SEA ABB=ON PLU=ON ("HATOUM MOKDAD H"/AU OR "HATOUM MOKDAD  
 HOLIA"/AU OR "HATOUM MOKDAD HOLIA N"/AU)  
 E MONAHAN K/AU  
 E MONAHAN M/AU  
 L64 37 SEA ABB=ON PLU=ON ("MONAHAN M"/AU OR "MONAHAN M K"/AU OR  
 "MONAHAN MARY K"/AU OR "MONAHAN MARY KATHERINE"/AU OR "MONAHAN  
 MARY KATHERINE C"/AU OR "MONAHAN MARY KETHERINE"/AU)  
 E LOWINGER T/AU  
 L65 46 SEA ABB=ON PLU=ON ("LOWINGER T B"/AU OR "LOWINGER TIMOTHY"/AU  
 OR "LOWINGER TIMOTHY B"/AU OR "LOWINGER TIMOTHY BRUNO"/AU OR  
 "LOWINGER TIMOTHY B"/AU)  
 E SCOTT W/AU  
 L66 158 SEA ABB=ON PLU=ON ("SCOTT W"/AU OR "SCOTT W J"/AU OR "SCOTT  
 W J JR"/AU OR "SCOTT W J M"/AU OR "SCOTT W J MERLE"/AU OR

"SCOTT W JAMES"/AU OR "SCOTT W JOHN H"/AU)  
 E SCOTT WILL/AU  
 L67 225 SEA ABB=ON PLU=ON ("SCOTT WILLIAM"/AU OR "SCOTT WILLIAM  
 J"/AU OR "SCOTT WILLIAM J JR"/AU OR "SCOTT WILLIAM JAMES"/AU  
 OR "SCOTT WILLIAM JAMES JR"/AU OR "SCOTT WILLIAM JOHNSTON"/AU  
 OR "SCOTT WILLIAM JOSEPH"/AU OR "SCOTT WILLIAM JR"/AU)  
 E SMITH R/AU  
 L68 1107 SEA ABB=ON PLU=ON ("SMITH R"/AU OR "SMITH R A"/AU OR "SMITH  
 R A A"/AU OR "SMITH R A D"/AU OR "SMITH R A G"/AU OR "SMITH R  
 A H"/AU OR "SMITH R A J"/AU OR "SMITH R A K"/AU OR "SMITH R A  
 L"/AU OR "SMITH R A W"/AU OR "SMITH R ABBEY"/AU OR "SMITH R  
 ANDREW"/AU OR "SMITH R ARNOLD"/AU)  
 E SMITH ROGER/AU  
 L69 293 SEA ABB=ON PLU=ON ("SMITH ROGER"/AU OR "SMITH ROGER A"/AU OR  
 "SMITH ROGER ALAN"/AU OR "SMITH ROGER ALTON"/AU OR "SMITH  
 ROGER ASTBURY"/AU)  
 E WOOD J/AU  
 L70 308 SEA ABB=ON PLU=ON ("WOOD J"/AU OR "WOOD J E"/AU OR "WOOD J E  
 JR"/AU OR "WOOD J EDWIN"/AU OR "WOOD J EDWIN JR"/AU OR "WOOD J  
 ELDRIDGE"/AU)  
 E WOOD J/AU  
 E WOOD JILL/AU  
 L71 35 SEA ABB=ON PLU=ON ("WOOD JILL"/AU OR "WOOD JILL E"/AU OR  
 "WOOD JILL ELIZABETH"/AU)  
 L72 45365 SEA ABB=ON PLU=ON BAYER/CS, PA  
 L73 5 SEA ABB=ON PLU=ON L56 AND (L58 OR L59 OR L60 OR L61 OR L62  
 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR L69 OR L70 OR  
 L71)  
 L74 5 SEA ABB=ON PLU=ON L56 AND L72  
 L75 5 SEA ABB=ON PLU=ON (L73 OR L74)  
 L76 1 SEA ABB=ON PLU=ON L56 NOT L75

=> b hcap

FILE 'HCAPLUS' ENTERED AT 12:06:14 ON 06 JUN 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jun 2005 VOL 142 ISS 24  
 FILE LAST UPDATED: 5 Jun 2005 (20050605/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all fhitr 175 tot

L75 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:874973 HCAPLUS  
 DN 139:364831  
 ED Entered STN: 07 Nov 2003  
 TI Preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase using

Search done by Noble Jarrell

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday;  
Sibley, Robert N.; Hatoum-Mokdad, Holia; Monahan,  
Mary-Katherine; Gunn, David E.; Lowinger, Timothy B.;  
Scott, William J.; Smith, Roger A.; Wood, Jill  
E.  
PA Bayer Corporation, USA  
SO U.S. Pat. Appl. Publ., 26 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
IC ICM C07D041-02  
ICS A61K031-4709; A61K031-4439  
INCL 514307000; 514313000; 546159000; 546143000; 514310000; 514336000;  
546268100  
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))  
Section cross-reference(s): 1, 7  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003207914	A1	20031106	US 2002-125369	20020419
PRAI	US 2001-367376P	P	20010420		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003207914	ICM	C07D041-02
	ICS	A61K031-4709; A61K031-4439
	INCL	514307000; 514313000; 546159000; 546143000; 514310000; 514336000; 546268100
US 2003207914	NCL	514/307.000; 514/313.000; 546/159.000; 546/143.000; 514/310.000; 514/336.000; 546/268.100
	ECLA	C07D213/40B; C07D215/38C; C07D401/12+217+213; C07D401/12+215+213

OS MARPAT 139:364831

AB Urea derivs. of general formula A-NHCONH-B, A'-CONH-B', and A''-NHCONH-B" or pharmaceutically acceptable salts thereof [wherein A = each (un)substituted tert-butylpyridyl, (trifluoromethyl)pyridyl, isopropylpyridyl, 2-methyl-2-butylpyridyl, or 3-methyl-3-pentylpyridyl; A' = each (un)substituted isoquinolinyl or isoquinolinyl; A" = substituted quinolinyl group; B, B' = independently, (un)substituted bridged cyclic structure of up to 30 carbon atoms of the formula -L-(ML1)q (wherein L comprises a cyclic moiety having at least 5 members and is bound directly to D; L1 comprises a cyclic moiety having at least 5 members; M is a bridging group having at least one atom, q is an integer of from 1-3, and each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur); B" = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with a cyclic structure bound directly to D containing at least 5 members with 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepared. These compds. are useful in treating raf-mediated diseases, in particular cancerous cell growth mediated by a raf kinase. All compds. exemplified, e.g. N-(4-tert-Butylpyridyl)-N'-(2,3-dichlorophenyl)urea, displayed IC50 of between 10 nM and 10 µM against ref kinase.

ST quinolylurea prepn raf kinase inhibitor; isoquinolylurea prepn raf kinase inhibitor; pyridylurea prepn raf kinase inhibitor; phenylpyridylurea prepn raf kinase inhibitor; cancer treatment urea prepn

IT Antitumor agents

Neoplasm

(preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(raf, raf-mediated diseases; preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase)

IT 6337-24-2P, 1-Methoxy-4-(4-nitrophenoxy)benzene 13472-85-0P,  
5-Bromo-2-methoxypyridine 18994-90-6P, 4-(1-Imidazolylmethyl)-1-  
nitrobenzene 27692-74-6P, 4-(4-Pyridinylmethyl)aniline 28232-34-0P,

5-Nitro-2-(4-methylphenoxy)pyridine 28232-52-2P, 3-(3-Pyridinyloxy)-1-nitrobenzene 31465-36-8P, 4-(4-Methoxyphenoxy)aniline 32361-76-5P, 3-(4-Nitrobenzyl)pyridine 36089-89-1P, 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene 51834-97-0P, 5-Hydroxy-2-methoxypyridine 56643-85-7P, 4-(1-Imidazolylmethyl)aniline 62248-47-9P, 4-(4-Butoxyphenyl)thio-1-nitrobenzene 62248-51-5P, 4-(4-Butoxyphenyl)thioaniline 64064-63-7P, 4-(6-Methyl-3-pyridinyloxy)-1-nitrobenzene 70991-08-1P, 4-(2-Pyridinylthio)aniline 85666-15-5P, 4-(3-Pyridinylmethyl)aniline 92575-23-0P, 3-(4-Pyridinylthio)aniline 116289-71-5P, 3-(3-Pyridinyloxy)aniline 178809-75-1P, 4-[1-Hydroxy-1-(4-pyridyl)methyl]-1-nitrobenzene 220000-87-3P, 2-(N-Methylcarbamoyl)-4-chloropyridine 228401-26-1P, 3-(Trifluoromethyl)-4-(4-pyridinylthio)nitrobenzene 228401-27-2P, 3-(Trifluoromethyl)-4-(4-pyridinylthio)aniline 228401-28-3P, 4-(4-Phenyl-2-thiazolylthio)-1-nitrobenzene 228401-29-4P, 4-(4-Phenyl-2-thiazolyl)thioaniline 228401-31-8P, 4-(6-Methyl-3-pyridinyloxy)aniline 228401-32-9P, 4-(3,4-Dimethoxyphenoxy)-1-nitrobenzene 228401-33-0P, 4-(3,4-Dimethoxyphenoxy)aniline 228401-36-3P, 5-Amino-2-(4-methylphenoxy)pyridine dihydrochloride 228401-37-4P, 4-(3-Thienylthio)-1-nitrobenzene 228401-38-5P, 4-(5-Pyrimidinylthio)aniline 228401-39-6P, 4-(2-Methoxy-5-pyridyloxy)-1-nitrobenzene 228401-40-9P, 4-(2-Methyl-4-pyridinyloxy)aniline 228401-41-0P, Methyl(4-nitrophenyl)-4-pyridylamine 228401-43-2P, 4-(3-Methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene 228401-44-3P, 4-(3-Carboxy-4-methoxyphenoxy)-1-nitrobenzene 229003-17-2P, 3-(5-Methyl-3-pyridinyloxy)-1-nitrobenzene 284462-84-6P, 4-(4-Methylsulfonylphenoxy)aniline 432050-13-0P, 4-(3-Thienylthio)aniline 432050-14-1P, 4-(2-Methoxy-5-pyridyloxy)aniline 432050-15-2P, Methyl(4-aminophenyl)-4-pyridylamine 432050-16-3P, 4-[1-Hydroxy-1-(4-pyridyl)methyl]aniline 473915-53-6P, 4-(4-tert-Butoxycarbamoylbenzyl)aniline 620625-96-9P, 4-[[2-(Methylcarbamoyl)-3-pyridyl]oxy]aniline

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase)

IT 139691-76-2, Raf Kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase)

IT 432050-17-4P, N-(4-tert-Butylpyridyl)-N'-(2,3-dichlorophenyl)urea  
432050-18-5P, N-(4-tert-Butylpyridyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea  
432050-19-6P, N,N'-Bis(2-methoxy-3-quinolinyl)urea 432050-20-9P,  
N-(4-tert-Butylpyridyl)-N'-[4-(4-chlorophenoxy)phenyl]urea 432050-21-0P,  
N-(5-Trifluoromethyl-2-pyridyl)-N'-[3-(4-pyridylthio)phenyl]urea  
432050-22-1P, N-(2-Methoxy-3-quinolinyl)-N'-[4-[2-(N-Methylcarbamoyl)-4-pyridyloxy]phenyl]urea 432050-41-4P 432050-42-5P  
432050-43-6P 432050-44-7P 432050-45-8P 432050-46-9P 432050-47-0P  
432050-48-1P 432050-49-2P 473915-54-7P 473915-55-8P 473915-56-9P,  
N-[1-(4-Methylpiperazinyl)-3-isoquinolinyl]-N'-[4-(4-pyridinyloxy)phenyl]urea 620625-86-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase)

IT 75-44-5, Phosgene 100-11-8, 4-Nitrobenzyl bromide 100-15-2,  
N-Methyl-4-nitroaniline 101-77-9, 4,4'-Methylenedianiline 101-79-1,  
4-(4-Chlorophenoxy)aniline 106-44-5, 4-Methylphenol, reactions  
109-00-2, 3-Hydroxypyridine 123-30-8, 4-Aminophenol 139-59-3,  
4-Phenoxyaniline 150-76-5, 4-Methoxyphenol 288-32-4, Imidazole,  
reactions 350-46-9, 1-Fluoro-4-nitrobenzene 400-74-8,  
2-Fluoro-5-nitrobenzotrifluoride 530-62-1, N,N'-Carbonyldiimidazole  
585-79-5, 1-Bromo-3-nitrobenzene 620-95-1, 3-Benzylpyridine 624-28-2,  
2,5-Dibromopyridine 626-61-9, 4-Chloropyridine 626-64-2,  
4-Hydroxypyridine 673-09-6, 4-(4-Pyridylthio)aniline 872-31-1,

3-Bromothiophene 1083-48-3, 4-(4-Nitrobenzyl)pyridine 1121-78-4,  
 5-Hydroxy-2-methylpyridine 1193-02-8, 4-Aminothiophenol 1849-36-1,  
 4-Nitrothiophenol 2033-89-8, 3,4-Dimethoxyphenol 2103-88-0,  
 2-Mercapto-4-phenylthiazole 3678-63-5, 4-Chloro-2-picoline 4548-45-2,  
 2-Chloro-5-nitropyridine 4556-23-4, 4-Mercaptopyridine 4595-59-9,  
 5-Bromopyrimidine 7379-35-3, 4-Chloropyridine hydrochloride  
 21101-60-0, 4-(4-Nitrophenylthio)phenol 22948-02-3, 3-Aminothiophenol  
 24424-99-5, Di-tert-butyl dicarbonate 25267-27-0, Iodobutane  
 25475-67-6, 3-Aminoisoquinoline 27163-00-4, 4-[(4-Methoxyphenyl)methylamino]aniline 29264-35-5, 4-(3-Carboxy-4-hydroxyphenoxy)-1-nitrobenzene 33252-26-5, 2-Amino-4-tert-butylpyridine 36265-31-3, 4-(4-Methylthiophenoxy)-1-nitrobenzene 41195-90-8, 2,3-Dichlorophenyl isocyanate 41295-20-9, 4-(4-Methylphenoxy)aniline 42732-49-0, 3-Hydroxy-5-methylpyridine 73322-01-7, 4-(2-Pyridinylthio)-1-nitrobenzene 74784-70-6, 2-Amino-5-(trifluoromethyl)pyridine 102877-78-1, 4-(4-Aminophenoxy)pyridine 150009-83-9, 3-Amino-2-methoxyquinoline 170893-64-8, 4-(4-Pyridylcarbonyl)aniline 284462-37-9 362688-26-4, 1-(4-Methylpiperazinyl)-3-aminoisoquinoline  
 RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase)


IT 432050-17-4P, N-(4-tert-Butylpyridyl)-N'-(2,3-dichlorophenyl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolyl, isoquinolyl or pyridyl ureas as inhibitors of raf kinase)

RN 432050-17-4 HCAPLUS

CN Urea, N-(2,3-dichlorophenyl)-N'-[4-(1,1-dimethylethyl)-2-pyridinyl]- (9CI)  
 (CA INDEX NAME)



L75 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:850357 HCAPLUS

DN 137:352907

ED Entered STN: 08 Nov 2002

TI Preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase for the treatment of tumors and/or cancerous cell growth

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday;

Wood, Jill E.; Robert, Sibley N.; Monahan, Mary-Katherine  
 ; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.;  
 Scott, William J.; Smith, Roger A.

PA Bayer Corporation, USA

SO U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 758,548.  
 CODEN: USXXCO

DT Patent

LA English

IC ICM C07D217-22

ICS C07D215-38

INCL 546143000

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002165394	A1	20021107	US 2001-777920	20010207
	ZA 2001005751	A	20030714	ZA 2001-5751	20010712

US 2002137774	A1	20020926	US 2001-907970	20010719
WO 2002062763	A2	20020815	WO 2002-US3361	20020207
WO 2002062763	A3	20021010		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003139605	A1	20030724	US 2002-71248	20020211
---------------	----	----------	---------------	----------

PRAI US 1999-115877P P 19990113

US 1999-257266 B2 19990225

US 1999-425228 B2 19991022

US 2001-758548 A2 20010112

US 1999-115878P P 19990113

US 2001-777920 A 20010207


US 2001-948915 A1 20010910

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002165394	ICM	C07D217-22
	ICS	C07D215-38
	INCL	546143000
US 2002165394	NCL	546/143.000; 546/159.000; 546/306.000; 546/014.000
	ECLA	C07C275/28; C07C275/30; C07C275/32; C07C275/36; C07C275/40; C07C311/29; C07C317/22; C07D209/48D5C1; C07D213/75B2; C07D213/75D3; C07D213/81E; C07D213/82H; C07D215/38C; C07D295/12A1; C07D295/12B1D4; C07D295/18B2D; C07D307/14; C07D401/12+215+213; C07D401/12+215+209; C07D401/12+217+213; C07D401/12+213+207
US 2002137774	NCL	514/353.000; 514/426.000; 514/596.000; 546/306.000; 548/557.000; 564/048.000; 564/049.000; 564/050.000
	ECLA	C07C275/28; C07C275/30; C07C275/32; C07C275/36; C07C275/40; C07C311/29; C07C317/22; C07D209/48D5C1; C07D213/75D3; C07D213/81E; C07D295/12A1; C07D295/12B1D4; C07D295/18B2D
WO 2002062763	ECLA	C07C275/36; C07D295/18B2D; C07D307/14; C07D401/12+215+213; C07D401/12+215+209; C07D401/12+217+213; C07D401/12+213+207; C07C275/40; C07C311/29; C07C317/22; C07D213/75B2; C07D213/82H; C07D215/38C; C07D217/22; C07D295/12A1; C07D295/12B1D4
US 2003139605	NCL	546/291.000
	ECLA	A61K031/17; C07C311/29; C07C317/22; C07D209/48D5C1; C07D213/75D3; C07D213/81E; C07D295/12A1; C07D295/12B1D4; C07D295/18B2D; A61K031/18; A61K031/24; A61K031/341; A61K031/40+A; A61K031/4035; A61K031/44+A; A61K031/4439; A61K031/4453; A61K031/495+A; A61K031/496; A61K031/5375; A61K031/5377; C07C275/28; C07C275/30; C07C275/32; C07C275/36; C07C275/40

OS MARPAT 137:352907

GI



AB Title compds. B-NHCONH-L-(M-L1)q (I) [B = (un)substituted pyridyl, quinolinyl, isoquinolinyl; L = 5 or 6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having at least one atom; q = 1-3; with proviso that L and L1 contain 0-4 hetero atoms, e.g., N, O and S] and their pharmaceutically acceptable salts were prepared. For example, coupling of aniline II, e.g., prepared from Et 3-hydroxybenzoate in 4-steps, with bis(trichloromethyl)carbonate followed by 3-tert-butylaniline afforded urea III. In in vitro raf kinase assays, 112-specific examples of compds. I inhibited kinase activity with IC50 values ranging from 10 nM-10  $\mu$ M. Compds. I are useful for the treatment of cancerous cell growth mediated by raf kinase.

ST quinoline urea prepn inhibition raf kinase antitumor; isoquinoline urea prepn inhibition raf kinase antitumor; pyridine urea prepn inhibition raf kinase antitumor

IT Antitumor agents  
Combinatorial chemistry  
Human  
Neoplasm  
Solid phase synthesis

(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

IT	228418-48-2P	284461-33-2P	284461-34-3P	284461-35-4P	284461-36-5P
	284461-37-6P	284461-38-7P	284461-39-8P	284461-40-1P	284461-41-2P
	284461-42-3P	284461-43-4P	284461-44-5P	284461-45-6P	284461-46-7P
	284461-47-8P	284461-48-9P	284461-49-0P	284461-50-3P	284461-51-4P
	284461-52-5P	284461-53-6P	284461-54-7P	284461-55-8P	284461-56-9P
	284461-57-0P	284461-58-1P	284461-59-2P	284461-60-5P	284461-61-6P
	284461-62-7P	284461-63-8P	284461-64-9P	284461-65-0P	284461-66-1P
	284461-67-2P	284461-68-3P	284461-69-4P	284461-70-7P	284461-71-8P
	284461-72-9P	284461-73-0P	284461-74-1P	284461-75-2P	284461-76-3P
	284461-77-4P	284461-78-5P	284461-79-6P	284461-80-9P	284461-81-0P
	284461-82-1P	284461-84-3P	284461-85-4P	284461-86-5P	284461-88-7P
	284461-89-8P	284461-90-1P	284461-91-2P	284461-92-3P	284461-93-4P
	284461-94-5P	284461-95-6P	284461-96-7P	284461-97-8P	284461-98-9P
	284462-00-6P	284462-01-7P	284462-02-8P	284462-03-9P	284462-04-0P
	284462-05-1P	284462-07-3P	284462-08-4P	284462-09-5P	284462-10-8P
	284462-11-9P	284462-12-0P	284462-13-1P	284462-15-3P	284462-16-4P
	284462-17-5P	284462-18-6P	284462-19-7P	284462-20-0P	284462-21-1P
	284462-22-2P	284462-23-3P	284462-24-4P	284462-25-5P	284462-26-6P
	284462-27-7P	284462-28-8P	284462-29-9P	284462-30-2P	284462-31-3P
	284462-32-4P	284462-34-6P	284462-35-7P	284462-70-0P	284670-98-0P


432050-20-9P, N-(4-tert-Butylpyridyl)-N'-(4-(4-chlorophenoxy)phenyl) Urea  
432050-22-1P 432050-23-2P 432050-24-3P  
432050-25-4P 432050-26-5P 432050-27-6P  
432050-28-7P 432050-52-7P 447457-08-1P 447457-09-2P 474642-44-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinolyl, isoquinolyl or pyridyl-ureas as

- inhibitors of raf kinase)
- IT 883-62-5P, 3-Methoxy-2-naphthoic acid 13041-60-6P, Methyl  
3-methoxy-2-naphthoate 27237-21-4P, 4-(3-Carboxyphenoxy)-1-nitrobenzene  
36089-89-1P, 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene 41513-02-4P,  
4-Bromo-3-(trifluoromethyl)phenyl isocyanate 50727-06-5P,  
5-Hydroxyisoindoline-1,3-dione 51727-15-2P, 4-Chloropyridine-2-carbonyl  
chloride hydrochloride 54579-63-4P, 4-(3-Carboxyphenoxy)aniline  
64064-63-7P 67291-63-8P, 2-Amino-3-methoxynaphthalene 71708-64-0P,  
4-(3-(N-Methylcarbamoyl)phenoxy)-1-nitrobenzene 77992-50-8P  
119431-22-0P, 3-Chloro-4-(2,2,2-trifluoroacetyl amino)phenol  
153435-79-1P, N-Methyl-3-bromobenzenesulfonamide 176977-85-8P, Methyl  
4-chloropyridine-2-carboxylate hydrochloride 220000-87-3P,  
4-Chloro-N-methyl-2-pyridinecarboxamide 228401-15-8P 228401-43-2P,  
4-(3-Methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene 228401-44-3P,  
4-(3-Carboxy-4-methoxyphenoxy)-1-nitrobenzene 252061-66-8P,  
5-Hydroxyisoindolin-1-one 284461-99-0P 284462-37-9P,  
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)aniline 284462-38-0P,  
5-(4-Nitrophenoxy)isoindoline-1,3-dione 284462-39-1P,  
5-(4-Aminophenoxy)isoindoline-1,3-dione 284462-40-4P,  
1-(4-tert-Butyl-2-nitrophenyl)-2,5-dimethylpyrrole 284462-41-5P,  
5-tert-Butyl-2-(2,5-dimethylpyrrolyl)aniline 284462-42-6P,  
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-methylaniline hydrochloride  
284462-43-7P 284462-44-8P, 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-  
chloroaniline 284462-45-9P, 4-Chloro-2-methoxy-5-  
(trifluoromethyl)aniline 284462-46-0P 284462-47-1P 284462-48-2P,  
5-(4-Nitrophenoxy)-2-methylisoindoline-1,3-dione 284462-49-3P,  
5-(4-Aminophenoxy)-2-methylisoindoline-1,3-dione 284462-51-7P,  
4-Chloro-2-(N-(2-morpholin-4-ylethyl)carbamoyl)pyridine 284462-52-8P  
284462-53-9P, 4-(1-Oxoisoindolin-5-yloxy)-1-nitrobenzene 284462-54-0P,  
4-(1-Oxoisoindolin-5-yloxy)aniline 284462-55-1P, 4-(3-  
Ethoxycarbonylphenoxy)-1-nitrobenzene 284462-56-2P 284462-57-3P  
284462-58-4P 284462-59-5P, 4-(3-(N-Methylsulfamoyl)phenyloxy)benzene  
284462-60-8P, 4-(3-(N-Methylsulfamoyl)phenyloxy)-1-nitrobenzene  
284462-61-9P, 4-(3-(N-Methylsulfamoyl)phenyloxy)aniline 284462-62-0P  
284462-63-1P, 4-Chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-  
carboxamide 284462-64-2P 284462-65-3P 284462-66-4P 284462-67-5P,  
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-aminophenyl) Urea  
284462-68-6P, N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-  
ethoxycarbonylphenyl) Urea 284462-71-1P 284462-97-1P 474642-51-8P,  
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(3-carboxyphenyl) Urea  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(intermediate; preparation of quinolyl, isoquinolyl or pyridyl-ureas as  
inhibitors of raf kinase)
- IT 50-21-5, Lactic acid, reactions 64-19-7, Acetic acid, reactions  
65-85-0, Benzoic acid, reactions 69-72-7, Salicylic acid, reactions  
75-75-2, Methanesulfonic acid 76-05-1, Trifluoroacetic acid, reactions  
77-92-9, Citric acid, reactions 85-47-2, 1-Naphthalenesulfonic acid  
87-69-4, Tartaric acid, reactions 90-64-2, Mandelic acid 98-11-3,  
Benzenesulfonic acid, reactions 103-82-2, Phenylacetic acid, reactions  
104-15-4, reactions 110-15-6, Succinic acid, reactions 110-16-7,  
Maleic acid, reactions 110-17-8, Fumaric acid, reactions 120-18-3,  
2-Naphthalenesulfonic acid 144-62-7, Oxalic acid, reactions 1493-13-6,  
Trifluoromethylsulfonic acid 6915-15-7, Malic acid 7647-01-0,  
Hydrochloric acid, reactions 7664-38-2, Phosphoric acid, reactions  
7664-93-9, Sulphuric acid, reactions 10035-10-6, Hydrobromic acid,  
reactions  
RL: RGT (Reagent); RACT (Reactant or reagent)  
(pharmaceutical salt; preparation of quinolyl, isoquinolyl or pyridyl-ureas  
as inhibitors of raf kinase)
- IT 139691-76-2, Raf kinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf  
kinase)
- IT 75-31-0, Isopropylamine, reactions 98-58-8, 4-Bromobenzenesulfonyl  
chloride 98-98-6, Picolinic acid 99-93-4, p-Hydroxyacetophenone

99-98-9, 4-(Dimethylamino)aniline 100-51-6, Benzyl alcohol, reactions  
 101-79-1, 4-(4-Chlorophenoxy)aniline 106-50-3, p-Phenylenediamine,  
 reactions 108-00-9, N,N-Dimethylethylenediamine 108-95-2, Phenol,  
 reactions 109-85-3, 2-Methoxyethylamine 110-13-4, Acetylacetone  
 123-30-8, 4-Aminophenol 123-39-7, N-Methylformamide 320-51-4,  
 4-Chloro-3-(trifluoromethyl)aniline 327-78-6, 4-Chloro-3-  
 (trifluoromethyl)phenyl isocyanate 349-65-5, 2-Methoxy-5-  
 (trifluoromethyl)aniline 350-46-9, 1-Fluoro-4-nitrobenzene 371-40-4,  
 4-Fluoroaniline 393-36-2, 4-Bromo-3-(trifluoromethyl)aniline 407-25-0,  
 Trifluoroacetic anhydride 462-08-8, 3-Aminopyridine 503-38-8,  
 Trichloromethyl chloroformate 610-35-5, 4-Hydroxyphthalic acid  
 619-08-9, 2-Chloro-4-nitrophenol 626-61-9, 4-Chloropyridine 883-99-8,  
 Methyl 3-hydroxy-2-naphthoate 1121-78-4, 5-Hydroxy-2-methylpyridine  
 1193-02-8, 4-Aminothiophenol 1664-40-0, N-Phenylethylenediamine  
 1877-71-0, Mono-methyl isophthalate 2038-03-1, 4-(2-  
 Aminoethyl)morpholine 2252-63-3, N-(4-Fluorophenyl)piperazine  
 2524-67-6, 4-Morpholinoaniline 2835-95-2, 5-Amino-2-methylphenol  
 2835-99-6, 4-Amino-3-methylphenol 2905-24-0, 3-Bromobenzenesulfonyl  
 chloride 3535-88-4, 5-Tert-Butyl-2-methoxyaniline 3964-52-1,  
 4-Amino-2-chlorophenol 4548-45-2, 2-Chloro-5-nitropyridine 4795-29-3,  
 Tetrahydrofurfurylamine 5369-19-7, 3-tert-Butylaniline 6310-19-6,  
 2-Nitro-4-tert-butylaniline 6628-77-9, 5-Amino-2-methoxypyridine  
 6927-86-2 7781-98-8, Ethyl 3-hydroxybenzoate 13154-24-0,  
 Triisopropylsilyl chloride 16588-75-3, 2-Methoxy-5-  
 (trifluoromethyl)phenyl isocyanate 22948-02-3, 3-Aminothiophenol  
 25900-61-2, 3-Methylcarbamoylaniline 26116-12-1, 2-Aminomethyl-1-  
 ethylpyrrolidine 27578-60-5, 1-(2-Aminoethyl)piperidine 30766-22-4,  
 Methyl 5-hydroxynicotinate 30806-83-8, Ethyl 4-isocyanatobenzoate  
 33252-26-5, 4-tert-Butyl-2-aminopyridine 34803-66-2,  
 N-(2-Pyridyl)piperazine 36265-31-3, 4-(4-Methylthiophenoxy)-1-  
 nitrobenzene 51639-48-6, N-(4-Acetylphenyl)piperazine 106164-64-1  
 150009-83-9, 3-Amino-2-methoxyquinoline 284462-72-2 284462-73-3,  
 4-Chloro-N-(2-hydroxyethyl)pyridine-2-carboxamide 284462-74-4,  
 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-methylaniline 474642-55-2  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf  
 kinase)  
 IT 29264-35-5P, 4-(3-Carboxy-4-hydroxyphenoxy)-1-nitrobenzene  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf  
 kinase)  
 IT 432050-22-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (drug candidate; preparation of quinolyl, isoquinolyl or pyridyl-ureas as  
 inhibitors of raf kinase)  
 RN 432050-22-1 HCAPLUS  
 CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amin  
 o]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L75 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2002:832761 HCAPLUS  
 DN 137:337791  
 ED Entered STN: 01 Nov 2002

TI Preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday;  
Sibley, Robert N.; Hatoum-Mokdad, Holia; Monahan,  
Mary-Katherine; Gunn, David E.; Lowinger, Timothy B.;  
Scott, William J.; Smith, Roger A.; Wood, Jill  
E.

PA Bayer Corporation, USA

SO PCT Int. Appl., 65 pp.  
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D213-40  
ICS C07D401-12; C07D215-38; A61K031-44; A61K031-4709; A61K031-4725;  
A61K031-47; A61P043-00

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))  
Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085857	A2	20021031	WO 2002-US12066	20020418
	WO 2002085857	A3	20030116		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2443950	AA	20021031	CA 2002-2443950	20020418
	EP 1379505	A2	20040114	EP 2002-725710	20020418
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005501813	T2	20050120	JP 2002-583384	20020418
PRAI	US 2001-838285	A	20010420		
	WO 2002-US12066	W	20020418		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002085857	ICM	C07D213-40
	ICS	C07D401-12; C07D215-38; A61K031-44; A61K031-4709; A61K031-4725; A61K031-47; A61P043-00
WO 2002085857	ECLA	C07D213/40B; C07D215/38C; C07D401/12+215+213; C07D401/12+217+213
JP 2005501813	FTERM	4C031/AA01; 4C031/DA02; 4C031/EA02; 4C031/JA02; 4C055/AA01; 4C055/BA02; 4C055/BA28; 4C055/BB17; 4C055/CA01; 4C055/DA06; 4C055/EA01; 4C063/AA01; 4C063/BB08; 4C063/BB09; 4C063/CC14; 4C063/CC15; 4C063/DD12; 4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC17; 4C086/BC28; 4C086/BC30; 4C086/GA08; 4C086/MA04; 4C086/MA22; 4C086/MA23; 4C086/MA35; 4C086/MA52; 4C086/MA55; 4C086/MA63; 4C086/NA14; 4C086/ZB26; 4C086/ZC20

OS MARPAT 137:337791

AB Title compds. A-D-B (I) [D = NHCONH; A = (un)substituted t-butylpyridyl, etc.; B = (un)substituted bridged cyclic structure, etc.] and analogs were prepared For instance, 4-tert-butyl-2-aminopyridine was coupled to 4-(4-pyridylmethyl)aniline (CH<sub>2</sub>Cl<sub>2</sub>, CDI, 0°) to give N-(4-tert-butylpyridyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea as a white solid. Example compds. had IC<sub>50</sub> between 10nM and 10µM for raf kinase. I are useful for the treatment of cancerous cell growth mediated by raf kinase.

ST inhibition raf kinase quinoline isoquinoline pyridine ureas prepn

IT Antitumor agents

## Human

## Neoplasm

(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

IT 139691-76-2, Raf kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

IT 432050-17-4P, N-(4-tert-Butylpyridyl)-N'-(2,3-dichlorophenyl)urea

432050-18-5P, N-(4-tert-Butylpyridyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea

432050-19-6P, N,N'-[2-Methoxyquinolin-3-yl]urea 432050-20-9P,

N-(4-tert-Butylpyridyl)-N'-[4-(4-chlorophenoxy)phenyl]urea 432050-21-0P,

N-[5-(Trifluoromethyl)pyridin-2-yl]-N'-[3-(4-pyridylthio)phenyl]urea

432050-22-1P 432050-41-4P 432050-42-5P 432050-43-6P

432050-44-7P 432050-45-8P 432050-46-9P 432050-47-0P 432050-48-1P

432050-49-2P 473915-54-7P 473915-55-8P 473915-56-9P 473915-57-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

IT 100-11-8, 4-Nitrobenzyl bromide 100-15-2, N-Methyl-4-nitroaniline

101-77-9, 4,4'-Methylenedianiline 101-79-1, 4-(4-Chlorophenoxy)aniline

106-44-5, 4-Methylphenol, reactions 109-00-2, 3-Hydroxypyridine

123-30-8, 4-Aminophenol 123-39-7, N-Methylformamide 139-59-3,

4-Phenoxyaniline 150-76-5, 4-Methoxyphenol 288-32-4, Imidazole,

reactions 350-46-9, 1-Fluoro-4-nitrobenzene 400-74-8,

2-Fluoro-5-nitrobenzotrifluoride 585-79-5, 1-Bromo-3-nitrobenzene

620-95-1, 3-Benzylpyridine 624-28-2, 2,5-Dibromopyridine 626-61-9,

4-Chloropyridine 673-09-6, 4-(4-Pyridylthio)aniline 872-31-1,

3-Bromothiophene 1083-48-3, 4-(4-Nitrobenzyl)pyridine 1121-78-4,

5-Hydroxy-2-methylpyridine 1849-36-1, 4-Nitrothiophenol 2033-89-8,

3,4-Dimethoxyphenol 2103-88-0, 2-Mercapto-4-phenylthiazole 3678-63-5

4548-45-2, 2-Chloro-5-nitropyridine 4556-23-4, 4-Mercaptopyridine

4595-59-9, 5-Bromopyrimidine 7379-35-3, 4-Chloropyridine hydrochloride

21101-60-0, 4-(4-Nitrophenylthio)phenol 22948-02-3, 3-Aminothiophenol

25267-27-0, Iodobutane 25475-67-6, 3-Aminoisoquinoline 27163-00-4,

4-[(4-Methoxyphenyl)methylamino]aniline 29264-35-5, 4-(3-Carboxy-4-

hydroxyphenoxy)-1-nitrobenzene 33252-26-5, 2-Amino-4-tert-butylpyridine

36265-31-3, 4-(4-Methylthiophenoxy)-1-nitrobenzene 41195-90-8,

2,3-Dichlorophenyl isocyanate 41295-20-9, 4-(4-Methylphenoxy)aniline

42732-49-0, 3-Hydroxy-5-methylpyridine 73322-01-7, 4-(2-Pyridinylthio)-1-

nitrobenzene 74784-70-6, 2-Amino-5-(trifluoromethyl)pyridine

102877-78-1 150009-83-9, 3-Amino-2-methoxyquinoline 170893-64-8,

4-(4-Pyridylcarbonyl)aniline 284462-37-9, 4-((2-(Methylcarbamoyl)pyridin-

4-yl)oxy)aniline 361551-95-3, 3-(4-Pyridylmethyl)aniline 362688-26-4,

1-(4-Methylpiperazinyl)-3-aminoisoquinoline

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

IT 6337-24-2P, 1-Methoxy-4-(4-nitrophenoxy)benzene 13472-85-0P,

5-Bromo-2-methoxypyridine 18994-90-6P, 4-(1-Imidazolylmethyl)-1-

nitrobenzene 27692-74-6P, 4-(4-Pyridinylmethyl)aniline 28232-34-0P,

5-Nitro-2-(4-methylphenoxy)pyridine 28232-52-2P, 3-(3-Pyridinyloxy)-1-

nitrobenzene 31465-36-8P, 4-(4-Methoxyphenoxy)aniline 32361-76-5P,

3-(4-Nitrobenzyl)pyridine 36089-89-1P, 4-(4-Methylsulfonylphenoxy)-1-

nitrobenzene 51834-97-0P, 5-Hydroxy-2-methoxypyridine 62248-47-9P,

4-(4-Butoxyphenyl)thio-1-nitrobenzene 62248-51-5P, 4-(4-

Butoxyphenyl)thioaniline 64064-63-7P, 4-(6-Methyl-3-pyridinyloxy)-1-

nitrobenzene 70991-08-1P, 4-(2-Pyridinylthio)aniline 92575-23-0P,

3-(4-Pyridinylthio)aniline 116289-71-5P, 3-(3-Pyridinyloxy)aniline

178809-75-1P, 4-[1-Hydroxy-1-(4-pyridyl)methyl]-1-nitrobenzene

220000-87-3P, 2-(N-Methylcarbamoyl)-4-chloropyridine 228401-26-1P,

3-(Trifluoromethyl)-4-(4-pyridinylthio)nitrobenzene 228401-27-2P,

3-(Trifluoromethyl)-4-(4-pyridinylthio)aniline 228401-28-3P,

4-[[4-Phenylthiazol-2-yl]sulfonyl]-1-nitrobenzene 228401-29-4P,

4-[[4-Phenylthiazol-2-yl]sulfanyl]aniline 228401-31-8P,  
 4-(6-Methyl-3-pyridinyloxy)aniline 228401-32-9P, 4-(3,4-Dimethoxyphenoxy)-1-nitrobenzene 228401-33-0P, 4-(3,4-Dimethoxyphenoxy)aniline 228401-36-3P, 5-Amino-2-(4-methylphenoxy)pyridine Dihydrochloride 228401-37-4P,  
 4-(3-Thienylthio)-1-nitrobenzene 228401-38-5P, 4-(5-Pyrimidinyloxy)aniline 228401-39-6P, 4-[[2-Methoxypyridin-5-yl]oxy]-1-nitrobenzene 228401-40-9P, 4-(2-Methyl-4-pyridinyloxy)aniline 228401-41-0P, Methyl(4-nitrophenyl)-4-pyridylamine 228401-43-2P,  
 4-(3-Methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene 228401-44-3P,  
 4-(3-Carboxy-4-methoxyphenoxy)-1-nitrobenzene 229003-17-2P,  
 3-(5-Methyl-3-pyridinyloxy)-1-nitrobenzene 473915-53-6P,  
 4-(4-tert-Butoxycarbamoylbenzyl)aniline

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

IT 432050-17-4P, N-(4-tert-Butylpyridyl)-N'-(2,3-dichlorophenyl)urea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

RN 432050-17-4 HCAPLUS

CN Urea, N-(2,3-dichlorophenyl)-N'-[4-(1,1-dimethylethyl)-2-pyridinyl]- (9CI)  
 (CA INDEX NAME)



L75 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:615574 HCAPLUS

DN 137:169425

ED Entered STN: 16 Aug 2002

TI Preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday;  
 Wood, Jill E.; Sibley, Robert N.; Monahan, Mary-Katherine  
 ; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.;  
 Scott, William J.; Smith, Roger A.

PA Bayer Corporation, USA

SO PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D215-38

ICS C07D401-12; A61K031-4406; A61K031-47; A61P035-00; C07D401-12;  
 C07D215-00; C07D213-00; C07D401-12; C07D215-00; C07D209-00

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062763	A2	20020815	WO 2002-US3361	20020207
	WO 2002062763	A3	20021010		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


US 2002165394 A1 20021107 US 2001-777920 20010207  
 PRAI US 2001-777920 A 20010207  
 US 1999-115877P P 19990113  
 US 1999-257266 B2 19990225  
 US 1999-425228 B2 19991022  
 US 2001-758548 A2 20010112

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002062763	ICM	C07D215-38
	ICS	C07D401-12; A61K031-4406; A61K031-47; A61P035-00; C07D401-12; C07D215-00; C07D213-00; C07D401-12; C07D215-00; C07D209-00
WO 2002062763	ECLA	C07C275/36; C07D295/18B2D; C07D307/14; C07D401/12+215+213; C07D401/12+215+209; C07D401/12+217+213; C07D401/12+213+207; C07C275/40; C07C311/29; C07C317/22; C07D213/75B2; C07D213/82H; C07D215/38C; C07D217/22; C07D295/12A1; C07D295/12B1D4
US 2002165394	NCL	546/143.000; 546/159.000; 546/306.000; 546/014.000
	ECLA	C07C275/28; C07C275/30; C07C275/32; C07C275/36; C07C275/40; C07C311/29; C07C317/22; C07D209/48D5C1; C07D213/75B2; C07D213/75D3; C07D213/81E; C07D213/82H; C07D215/38C; C07D295/12A1; C07D295/12B1D4; C07D295/18B2D; C07D307/14; C07D401/12+215+213; C07D401/12+215+209; C07D401/12+217+213; C07D401/12+213+207

OS MARPAT 137:169425

GI



II

AB Title compds., e.g., RNHCONHZOR1 [I; R = C<sub>6</sub>H<sub>4</sub>(CMe<sub>3</sub>)-3, 2-methoxy-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-methoxy-3-quinolyl, etc.; R1 = (un)substituted acylphenyl, -acylpyridinyl, etc.; Z = (un)substituted 1,3- or -1,4-phenylene] were prepared. Thus, 4-(H<sub>2</sub>N)C<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>(CONHMe)-4 (preparation given) was condensed with 3-(Me<sub>3</sub>C)C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> and CO(OCCl<sub>3</sub>)<sub>2</sub> to give title compound II. Data for biol. activity of title compds. were given.

ST acylphenoxyphenylurea prepn raf kinase inhibitor; antitumor agent  
 acylphenoxyphenylurea prepn

IT Antitumor agents  
 Human  
 (preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

IT Neoplasm  
 (treatment; preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

IT 139691-76-2, Raf kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (mediated disorders; treatment; preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

IT 228418-48-2P 284461-33-2P 284461-34-3P 284461-35-4P 284461-36-5P  
 284461-37-6P 284461-38-7P 284461-39-8P 284461-40-1P 284461-41-2P  
 284461-42-3P 284461-43-4P 284461-44-5P 284461-45-6P 284461-46-7P  
 284461-47-8P 284461-48-9P 284461-49-0P 284461-50-3P 284461-51-4P  
 284461-52-5P 284461-53-6P 284461-54-7P 284461-55-8P 284461-56-9P  
 284461-57-0P 284461-58-1P 284461-59-2P 284461-60-5P 284461-61-6P  
 284461-62-7P 284461-63-8P 284461-64-9P 284461-65-0P 284461-66-1P  
 284461-67-2P 284461-68-3P 284461-69-4P 284461-70-7P 284461-71-8P  
 284461-72-9P 284461-73-0P 284461-74-1P 284461-75-2P 284461-76-3P  
 284461-77-4P 284461-78-5P 284461-79-6P 284461-80-9P 284461-81-0P  
 284461-82-1P 284461-83-2P 284461-84-3P 284461-85-4P 284461-86-5P  
 284461-88-7P 284461-89-8P 284461-90-1P 284461-91-2P 284461-92-3P  
 284461-93-4P 284461-94-5P 284461-95-6P 284461-96-7P 284461-97-8P  
 284461-98-9P 284461-99-0P 284462-00-6P 284462-01-7P 284462-02-8P  
 284462-03-9P 284462-04-0P 284462-05-1P 284462-07-3P 284462-08-4P  
 284462-09-5P 284462-10-8P 284462-11-9P 284462-12-0P 284462-13-1P  
 284462-15-3P 284462-16-4P 284462-17-5P 284462-18-6P 284462-19-7P  
 284462-20-0P 284462-21-1P 284462-22-2P 284462-23-3P 284462-24-4P  
 284462-25-5P 284462-26-6P 284462-27-7P 284462-28-8P 284462-29-9P  
 284462-30-2P 284462-31-3P 284462-32-4P 284462-34-6P 284462-35-7P  
 284462-70-0P 284670-98-0P 432050-22-1P 432050-23-2P  
 432050-24-3P 432050-25-4P 432050-26-5P  
 432050-27-6P 432050-28-7P 432050-52-7P 432050-53-8P  
 447457-08-1P 447457-09-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase  
 inhibitors)

IT 75-31-0, Isopropylamine, reactions 98-58-8, 4-Bromobenzenesulfonyl  
 chloride 98-98-6, Picolinic acid 99-93-4, p-Hydroxyacetophenone  
 99-98-9, 4-(Dimethylamino)aniline 100-51-6, Benzyl alcohol, reactions  
 101-79-1, 4-(4-Chlorophenoxy)aniline 106-50-3, p-Phenylenediamine,  
 reactions 108-95-2, Phenol, reactions 109-85-3, 2-Methoxyethylamine  
 123-30-8, 4-Aminophenol 123-54-6, Acetylacetone, reactions 320-51-4,  
 4-Chloro-3-(trifluoromethyl)aniline 327-78-6, 4-Chloro-3-  
 (trifluoromethyl)phenyl isocyanate 349-65-5, 2-Methoxy-5-  
 (trifluoromethyl)aniline 350-46-9, 1-Fluoro-4-nitrobenzene 371-40-4,  
 4-Fluoroaniline 393-36-2, 4-Bromo-3-(trifluoromethyl)aniline 462-08-8,  
 3-Aminopyridine 490-79-9, 2,5-Dihydroxybenzoic acid 591-27-5,  
 3-Aminophenol 610-35-5, 4-Hydroxyphthalic acid 619-08-9,  
 2-Chloro-4-nitrophenol 626-61-9, 4-Chloropyridine 883-99-8, Methyl  
 3-hydroxy-2-naphthoate 1121-78-4, 5-Hydroxy-2-methylpyridine  
 1193-02-8, 4-Aminothiophenol 1664-40-0, N-Phenylethylenediamine  
 1877-71-0, Mono-Methyl isophthalate 2038-03-1, 4-(2-  
 Aminoethyl)morpholine 2524-67-6, 4-Morpholinoaniline 2835-95-2,  
 5-Amino-2-methylphenol 2835-99-6, 4-Amino-3-methylphenol 2905-24-0,  
 3-Bromobenzenesulfonyl chloride 3535-88-4, 5-tert-Butyl-2-methoxyaniline  
 3964-52-1, 4-Amino-2-chlorophenol 4548-45-2, 2-Chloro-5-nitropyridine  
 4795-29-3, Tetrahydrofurfurylamine 5369-19-7, 3-tert-Butylaniline  
 6310-19-6, 2-Nitro-4-tert-butylaniline 6628-77-9, 5-Amino-2-  
 methoxypyridine 6927-86-2, 4-(4-Acetylphenoxy)aniline hydrochloride  
 7781-98-8, Ethyl 3-hydroxybenzoate 13154-24-0, Triisopropylsilyl  
 chloride 22948-02-3, 3-Aminothiophenol 25900-61-2,  
 3-(Methylcarbamoyl)aniline 26116-12-1, 2-(Aminomethyl)-1-  
 ethylpyrrolidine 27578-60-5, 1-(2-Aminoethyl)piperidine 30766-22-4,  
 Methyl 5-hydroxynicotinate 30806-83-8, Ethyl 4-isocyanatobenzoate  
 33252-26-5, 2-Amino-4-tert-butylpyridine 34803-66-2,  
 N-(2-Pyridyl)piperazine 36265-31-3, 4-(4-(Methylthio)phenoxy)-1-  
 nitrobenzene 106164-64-1 150009-83-9, 3-Amino-2-methoxyquinoline  
 284462-71-1 284462-72-2, 3-Chloro-6-(N-acetylamino)-4-  
 (trifluoromethyl)anisole 284462-73-3, 4-Chloro-N-(2-  
 hydroxyethyl)pyridine-2-carboxamide 447457-10-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase  
 inhibitors)

IT 883-62-5P, 3-Methoxy-2-naphthoic acid 13041-60-6P, Methyl  
 3-methoxy-2-naphthoate 27237-21-4P, 4-(3-Carboxyphenoxy)-1-nitrobenzene  
 36089-89-1P, 4-(4-(Methylsulfonyl)phenoxy)-1-nitrobenzene 41513-02-4P,  
 4-Bromo-3-(trifluoromethyl)phenyl isocyanate 50727-06-5P,  
 5-Hydroxyisoindoline-1,3-dione 51727-15-2P, 4-Chloropyridine-2-carbonyl  
 chloride hydrochloride 54579-63-4P, 4-(3-Carboxyphenoxy)aniline  
 64064-63-7P, 4-((2-Methylpyridin-5-yl)oxy)-1-nitrobenzene 67291-63-8P,  
 2-Amino-3-methoxynaphthalene 71708-64-0P 77992-50-8P,  
 4-Bromo-3-(trifluoromethyl)aniline hydrochloride 119431-22-0P,  
 3-Chloro-4-(2,2,2-trifluoroacetyl amino)phenol 153435-79-1P,  
 N-Methyl-3-bromobenzenesulfonamide 176977-85-8P, Methyl  
 4-chloropyridine-2-carboxylate hydrochloride 220000-87-3P 228401-15-8P  
 228401-43-2P, 4-(3-Methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene  
 228401-44-3P, 4-(3-Carboxy-4-methoxyphenoxy)-1-nitrobenzene  
 252061-66-8P, 5-Hydroxyisoindolin-1-one 284462-37-9P 284462-38-0P,  
 5-(4-Nitrophenoxy)isoindoline-1,3-dione 284462-39-1P,  
 5-(4-Aminophenoxy)isoindoline-1,3-dione 284462-40-4P,  
 1-(4-tert-Butyl-2-nitrophenyl)-2,5-dimethylpyrrole 284462-41-5P  
 284462-42-6P 284462-43-7P 284462-44-8P 284462-45-9P,  
 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline 284462-46-0P,  
 4-[3-(N-Methylcarbamoyl)-4-methoxyphenoxy]-1-nitrobenzene 284462-47-1P,  
 4-[3-(N-Methylcarbamoyl)-4-methoxyphenoxy]aniline 284462-48-2P,  
 5-(4-Nitrophenoxy)-2-methylisoindoline-1,3-dione 284462-49-3P,  
 5-(4-Aminophenoxy)-2-methylisoindoline-1,3-dione 284462-51-7P,  
 4-Chloro-2-[N-(2-morpholin-4-ylethyl)carbamoyl]pyridine 284462-52-8P  
 284462-53-9P, 4-(1-Oxoisoindolin-5-yloxy)-1-nitrobenzene 284462-54-0P,  
 4-(1-Oxoisoindolin-5-yloxy)aniline 284462-55-1P, 4-(3-  
 Ethoxycarbonylphenoxy)-1-nitrobenzene 284462-56-2P 284462-57-3P  
 284462-58-4P 284462-59-5P 284462-60-8P, 4-[3-(N-  
 Methylsulfamoyl)phenoxy]-1-nitrobenzene 284462-61-9P,  
 4-[3-(N-Methylsulfamoyl)phenoxy]aniline 284462-62-0P 284462-63-1P,  
 4-Chloro-N-[2-(triisopropylsilyloxy)ethyl]pyridine-2-carboxamide  
 284462-64-2P 284462-65-3P, 4-((2-Methoxycarbonylpyridin-5-yl)oxy)-1-  
 nitrobenzene 284462-66-4P 284462-67-5P 284462-68-6P 284462-69-7P  
 284462-97-1P 432050-20-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase  
 inhibitors)  
 IT 432050-22-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase  
 inhibitors)  
 RN 432050-22-1 HCAPLUS  
 CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amin  
 o]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L75 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2002:409267 HCAPLUS  
 DN 137:6098  
 ED Entered STN: 31 May 2002  
 TI Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors  
 IN Dumas, Jacques; Riedl, Bernd; Khire, Uday;  
 Sibley, Robert N.; Hatoum-Mokdad, Holia; Monahan,

Mary-katherine; Gunn, David E.; Lowinger, Timotthy B.;  
 Scott, William J.; Smith, Roger A.; Wood, Jill  
 E.

PA Bayer Corporation, USA

SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U. S. Ser. No. 778,039.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-506

ICS A61K031-501; A61K031-497; A61K031-4725; A61K031-4709

INCL 514310000

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2002065296	A1	20020530	US 2001-838286	20010420	
	US 2003139605	A1	20030724	US 2002-71248	20020211	
	CA 2443952	AA	20021031	CA 2002-2443952	20020417	
	WO 2002085859	A1	20021031	WO 2002-US12064	20020417	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	EP 1379507	A1	20040114	EP 2002-725709	20020417	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP 2004537511	T2	20041216	JP 2002-583386	20020417	
PRAI	US 1999-115878P	P	19990113			
	US 1999-257265	B1	19990225			
	US 1999-425229	A2	19991022			
	US 2001-778039	A2	20010207			
	US 1999-115877P	P	19990113			
	US 1999-257266	B2	19990225			
	US 1999-425228	B1	19991022			
	US 2001-838286	A	20010420			
	US 2001-948915	A1	20010910			
	WO 2002-US12064	W	20020417			

#### CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002065296	ICM	A61K031-506
	ICS	A61K031-501; A61K031-497; A61K031-4725; A61K031-4709
	INCL	514310000
US 2002065296	NCL	514/310.000; 514/313.000; 514/336.000; 514/337.000; 514/252.030; 514/252.040; 514/255.050; 514/256.000
	ECLA	A61K031/17; A61K031/18; A61K031/24; A61K031/341; A61K031/40+A; A61K031/4035; A61K031/44; A61K031/44+A; A61K031/4439; A61K031/4453; A61K031/47; A61K031/4709; A61K031/4725; A61K031/495+A; A61K031/496; A61K031/5375; A61K031/5377; C07D213/75D3; C07D215/38C; C07D217/22; C07D401/12+215+213
US 2003139605	NCL	546/291.000
	ECLA	A61K031/17; C07C311/29; C07C317/22; C07D209/48D5C1; C07D213/75D3; C07D213/81E; C07D295/12A1; C07D295/12B1D4; C07D295/18B2D; A61K031/18; A61K031/24; A61K031/341; A61K031/40+A; A61K031/4035; A61K031/44+A; A61K031/4439; A61K031/4453; A61K031/495+A; A61K031/496; A61K031/5375; A61K031/5377; C07C275/28; C07C275/30; C07C275/32; C07C275/36; C07C275/40
WO 2002085859	ECLA	A61K031/44; A61K031/47; A61K031/4709; A61K031/4725;

C07D213/75D3; C07D215/38C; C07D217/22;  
C07D401/12+215+213; C07D401/12+217+213

JP 2004537511 FTERM 4C031/JA09; 4C034/AL05; 4C055/AA01; 4C055/BA01;  
4C055/BA02; 4C055/BA53; 4C055/BB17; 4C055/CA01;  
4C055/DA06; 4C055/DA28; 4C055/DA42; 4C055/DA47;  
4C055/DB10; 4C055/DB17; 4C055/EA01; 4C063/AA01;  
4C063/BB07; 4C063/BB09; 4C063/CC14; 4C063/CC15;  
4C063/DD07; 4C063/DD12; 4C063/EE01; 4C086/AA01;  
4C086/AA03; 4C086/BC17; 4C086/BC28; 4C086/BC30;  
4C086/BC50; 4C086/GA07; 4C086/GA08; 4C086/GA12;  
4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA01;  
4C086/ZA02; 4C086/ZA36; 4C086/ZA45; 4C086/ZA54;  
4C086/ZA59; 4C086/ZA67; 4C086/ZA68; 4C086/ZA75;  
4C086/ZA86; 4C086/ZA89; 4C086/ZA94; 4C086/ZA96;  
4C086/ZA97; 4C086/ZB02; 4C086/ZB05; 4C086/ZB11;  
4C086/ZB13; 4C086/ZB15; 4C086/ZB26; 4C086/ZB33;  
4C086/ZB35; 4C086/ZC21; 4C086/ZC35

OS MARPAT 137:6098

AB This invention relates to the use of a group of heteroaryl ureas (I; for example, N-(2-methoxy-3-quinolyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea) containing N in treating p38 mediated diseases, and pharmaceutical compns. for use in such therapy. I is A-NHC(O)NH-B or a pharmaceutically acceptable salt thereof, wherein A is a substituted or unsubstituted pyridyl, quinoliny or isoquinoliny group, B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 50 C atoms with a cyclic structure bound directly to N, containing at least 5 cyclic members with 0-4 members of groups consisting of N, O and S. Information about the substituents for A and B are given in the claims. Although the methods of preparation are not claimed, 37 example preps. are included as well as examples of preparation of intermediates. No pharmacol. data is included.

ST nitrogen heteroaryl urea prepn p38 kinase inhibitor; pyridyl urea prepn p38 kinase inhibitor; quinolyl urea prepn p38 kinase inhibitor; isoquinolyl urea prepn p38 kinase inhibitor

IT Infection  
(Chagas' disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Inflammation  
(Crohn's disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Intestine, disease  
(Crohn's; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Disease, animal  
(Jarisch-Herxheimer reaction; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Malaria  
(Plasmodium falciparum malaria and cerebral malaria; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treating)

IT Antimalarials  
(Plasmodium falciparum malaria and cerebral malaria; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)

IT Toxins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Shiga-like toxin, effects of toxins from Escherichia coli infection; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Respiratory distress syndrome  
(adult; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Hepatitis  
(alc.; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

IT Transplant rejection

- (allotransplant; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Lung  
(alveolus, injury; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Antiarteriosclerotics  
(antiatherosclerotics; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)
- IT Aneurysm  
(aortic; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Meningitis  
(bacterial; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Necrosis  
(bowel; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Bronchi, disease  
Inflammation  
(bronchitis, obliterative; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Injury  
(cerebral; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Pneumoconiosis  
(coal worker's; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Eye, disease  
(cornea, ulcer; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Ulcer  
(corneal; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Radiation  
(damage, injury/toxicity following administration of monoclonal antibodies; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Cartilage, disease  
(degeneration; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Multiple sclerosis  
(demyelination and oligiodendrocyte loss in; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Liver, disease  
(during acute inflammation; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Toxins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(enterotoxin A, effects of toxins from Staphylococcus infection; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Skin, disease  
(epidermolysis bullosa, dystrophobic; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Liver, disease  
(failure; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Lung, disease  
(fibrosis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Nervous system agents  
(for demyelating disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)
- IT Wound healing  
(impaired wound healing in infection; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)

- IT Helicobacter pylori  
(infection during peptic ulcer disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Borrelia burgdorferi
- Cytomegalovirus
- Human immunodeficiency virus
- Influenza virus
- Theiler's murine encephalomyelitis virus
- Treponema pallidum  
(infections from; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Brain, disease
- Reperfusion  
(injury; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Leukemia  
(lymphocytic, inhibitors; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)
- IT Neoplasm  
(metastasis, inhibitors; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)
- IT Heterocyclic compounds  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(nitrogen, heteroaryl ureas; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)
- IT Bone, disease  
(osteopenia, mediated by MMP activity; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Inflammation
- Pancreas, disease  
(pancreatitis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Ulcer  
(peptic, Helicobacter pylori infection during; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Osteoporosis  
(postmenopausal; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treating)
- IT Human  
(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)
- IT Allergy
- Alzheimer's disease
- Arthritis
- Asthma
- Diabetes mellitus
- Rheumatoid arthritis
- Tuberculosis  
(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treating)
- IT Encephalitis
- Myelodysplastic syndromes
- Periodontium, disease
- Psoriasis
- Rheumatic fever
- Silicosis  
(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)
- IT Allergy inhibitors
- Anti-Alzheimer's agents
- Anti-infective agents
- Anti-inflammatory agents
- Antiarthritics

Antiasthmatics  
 Antibacterial agents  
 Anticoagulants  
 Antidiabetic agents  
 Antirheumatic agents  
 Antitumor agents  
 Cardiovascular agents  
 Contraceptives  
 Tuberculostatics  
 (preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)  
 IT Biliary tract, disease  
 (primary biliary cirrhosis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (proteinuria; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Fibrosis  
 Sarcoidosis  
 (pulmonary; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Injury  
 (reperfusion; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Bone  
 (resorption; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Lung, disease  
 (sarcoidosis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Shock (circulatory collapse)  
 (septic; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Inflammation  
 (systemic inflammatory response syndrome; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Lupus erythematosus  
 (systemic; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Disease, animal  
 (temporomandibular joint; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Joint, anatomical  
 (temporomandibular, disease; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Osteoporosis  
 (therapeutic agents, postmenopausal; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for use as)  
 IT Shock (circulatory collapse)  
 (toxic shock syndrome; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Digestive tract, disease  
 (ulcer, peptic, Helicobacter pylori infection during; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT Inflammation  
 Intestine, disease  
 (ulcerative colitis; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors for treatment of)  
 IT 165245-96-5, p38 Kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; preparation of heteroaryl ureas containing nitrogen hetero-atoms as)  
 IT 673-09-6P, 4-(4-Pyridylthio)aniline 6337-24-2P, 1-Methoxy-4-(4-nitrophenoxy)benzene 13472-85-0P, 5-Bromo-2-methoxypyridine

18994-90-6P, 4-(1-Imidazolylmethyl)-1-nitrobenzene 27237-21-4P,  
 4-(3-Carboxyphenoxy)-1-nitrobenzene 27692-74-6P, 4-(4-Pyridinylmethyl)aniline 28232-34-0P, 5-Nitro-2-(4-methylphenoxy)pyridine 28232-52-2P, 3-(3-Pyridinyloxy)-1-nitrobenzene 29264-35-5P,  
 4-(3-Carboxy-4-hydroxyphenoxy)-1-nitrobenzene 31465-36-8P,  
 4-(4-Methoxyphenoxy)aniline 32361-76-5P, 3-(4-Nitrobenzyl)pyridine 36089-89-1P, 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene 50727-06-5P,  
 5-Hydroxyisoindoline-1,3-dione 51727-15-2P, 4-Chloropyridine-2-carbonyl chloride hydrochloride 51834-97-0P, 5-Hydroxy-2-methoxypyridine 56643-85-7P, 4-(1-Imidazolylmethyl)aniline 62248-47-9P,  
 4-[(4-Butoxyphenyl)thio]-1-nitrobenzene 62248-51-5P,  
 4-(4-Butoxyphenyl)thioaniline 64064-63-7P, 4-(6-Methyl-3-pyridinyloxy)-1-nitrobenzene 70991-08-1P, 4-(2-Pyridinylthio)aniline 71708-64-0P,  
 4-[3-(N-Methylcarbamoyl)phenoxy]-1-nitrobenzene 85666-15-5P,  
 4-[(3-Pyridinyl)methyl]aniline 92575-23-0P, 3-(4-Pyridinylthio)aniline 99586-65-9P, 4-Chloro-2-pyridinecarboxamide 102877-78-1P 116289-71-5P,  
 3-(3-Pyridinyloxy)aniline 135680-03-4P, 4-(4-tert-Butoxycarbonylaminobenzyl)aniline 176977-85-8P, Methyl 4-chloropyridine-2-carboxylate hydrochloride 178809-75-1P,  
 4-[Hydroxy(4-pyridyl)methyl]-1-nitrobenzene 220000-87-3P 228401-26-1P,  
 3-(Trifluoromethyl)-4-(4-pyridinylthio)nitrobenzene 228401-27-2P,  
 3-(Trifluoromethyl)-4-(4-pyridinylthio)aniline 228401-28-3P,  
 4-[(4-Phenyl-2-thiazolyl)thio]-1-nitrobenzene 228401-29-4P,  
 4-[(4-Phenyl-2-thiazolyl)thio]aniline 228401-31-8P, 4-(6-Methyl-3-pyridinyloxy)aniline 228401-32-9P, 4-(3,4-Dimethoxyphenoxy)-1-nitrobenzene 228401-33-0P, 4-(3,4-Dimethoxyphenoxy)aniline 228401-34-1P, 3-(6-Methyl-3-pyridinyloxy)-1-nitrobenzene 228401-35-2P,  
 3-(6-Methyl-3-pyridinyloxy)aniline 228401-36-3P, 5-Amino-2-(4-methylphenoxy)pyridine Dihydrochloride 228401-37-4P,  
 4-(3-Thienylthio)-1-nitrobenzene 228401-38-5P, 4-(5-Pyrimidinylloxy)aniline 228401-39-6P, 4-[(2-Methoxy-5-pyridyl)oxy]-1-nitrobenzene 228401-40-9P, 4-(2-Methyl-4-pyridinyloxy)aniline 228401-41-0P, Methyl(4-nitrophenyl)(4-pyridyl)amine 228401-43-2P,  
 4-(3-Methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene 228401-44-3P,  
 4-(3-Carboxy-4-methoxyphenoxy)-1-nitrobenzene 284462-37-9P,  
 4-[2-(N-Methylcarbamoyl)-4-pyridyloxy]aniline 284462-38-0P,  
 5-(4-Nitrophenoxy)isoindoline-1,3-dione 284462-39-1P,  
 5-(4-Aminophenoxy)isoindoline-1,3-dione 284462-46-0P,  
 4-[3-(N-Methylcarbamoyl)-4-methoxyphenoxy]-1-nitrobenzene 284462-47-1P,  
 4-[3-(N-Methylcarbamoyl)-4-methoxyphenoxy]aniline 284462-55-1P,  
 4-(3-Ethoxycarbonylphenoxy)-1-nitrobenzene 284462-56-2P,  
 4-(3-N-Methylcarbamoylphenoxy)aniline 284462-78-8P, 3-[2-(N-Methylcarbamoyl)-4-pyridyloxy]aniline 284462-79-9P, 3-(2-Carbamoyl-4-pyridyloxy)aniline 284462-80-2P, 4-(2-Carbamoyl-4-pyridyloxy)aniline 284462-84-6P, 4-(4-Methylsulfonylphenoxy)aniline 432050-13-0P,  
 4-(3-Thienylthio)aniline 432050-14-1P, 4-[(2-Methoxy-5-pyridyl)oxy]aniline 432050-15-2P, Methyl(4-aminophenyl)(4-pyridyl)amine 432050-16-3P, 4-[Hydroxy(4-pyridyl)methyl]aniline  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)

IT 284461-54-7P, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(1,3-dioxoisoindolin-5-yloxy)phenyl]urea 284670-98-0P, N,N'-Bis[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 432050-17-4P  
 432050-18-5P 432050-19-6P, N,N'-Bis(2-methoxy-3-quinolinyl)urea 432050-20-9P 432050-21-0P, N-[5-Trifluoromethyl-2-pyridyl]-N'-[3-(4-pyridylthio)phenyl]urea 432050-22-1P, N-(2-Methoxy-3-quinolinyl)-N'-[4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)phenyl]urea 432050-23-2P  
 , N-(2-Methoxy-3-quinolyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea 432050-24-3P, N-(2-Methoxy-3-quinolyl)-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 432050-25-4P, N-(2-Methoxy-3-quinolyl)-N'-[3-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 432050-26-5P,  
 N-(2-Methoxy-3-quinolyl)-N'-[3-(2-carbamoyl-4-pyridyloxy)phenyl]urea 432050-27-6P, N-(2-Methoxy-3-quinolyl)-N'-[4-[3-(N-isopropylcarbamoyl)phenoxy]phenyl]urea 432050-28-7P,

N-(2-Methoxy-3-quinolyl)-N'-[4-[4-methoxy-3-(N-methylcarbamoyl)phenoxy]phenyl]urea 432050-29-8P,  
 N-(3-Isoquinolyl)-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea  
 432050-30-1P, N-(4-tert-Butyl-2-pyridinyl)-N'-(4-methylphenyl)urea  
 432050-31-2P, N-(4-tert-Butyl-2-pyridinyl)-N'-(4-fluorophenyl)urea  
 432050-32-3P, N-(4-tert-Butyl-2-pyridinyl)-N'-(1-naphthyl)urea  
 432050-33-4P, N-(4-tert-Butyl-2-pyridinyl)-N'-[4-(4-methoxyphenoxy)phenyl]urea 432050-34-5P, N-(5-Trifluoromethyl-2-pyridinyl)-N'-[4-(4-pyridylmethyl)phenyl]urea 432050-35-6P,  
 N-(3-Isoquinolyl)-N'-(4-methylphenyl)urea 432050-36-7P,  
 N-(3-Isoquinolyl)-N'-(4-fluorophenyl)urea 432050-37-8P,  
 N-(3-Isoquinolyl)-N'-(2,3-dichlorophenyl)urea 432050-38-9P,  
 N-(3-Isoquinolyl)-N'-(1-naphthyl)urea 432050-39-0P,  
 N-(3-Isoquinolyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea  
 432050-40-3P, N-(3-Quinolyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea  
 432050-41-4P, N-(4-tert-Butyl-2-pyridyl)-N'-(4-(4-methylphenoxy)phenyl)urea 432050-42-5P, N-(4-tert-Butyl-2-pyridyl)-N'-(4-(4-pyridyloxy)phenyl)urea 432050-43-6P, N-(4-tert-Butyl-2-pyridyl)-N'-(4-(4-pyridinylthio)phenyl)urea 432050-44-7P, N-(4-tert-Butyl-2-pyridyl)-N'-(3-(4-pyridinylthio)phenyl)urea 432050-45-8P 432050-46-9P  
 432050-47-0P 432050-48-1P 432050-49-2P 432050-50-5P 432050-51-6P,  
 N-(1-(4-Methyl-1-piperazinyl)isoquinol-3-yl)-N'-(4-(4-pyridyl)methyl)phenyl)urea 432050-52-7P, N-(Isoquinol-3-yl)-N'-(4-(3-(methylcarbamoyl)phenoxy)phenyl)urea 432050-53-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)

IT 75-31-0, Isopropylamine, reactions 86-84-0, 1-Naphthyl isocyanate  
 98-98-6, Picolinic acid 100-11-8, 4-Nitrobenzyl bromide 100-15-2,  
 N-Methyl-4-nitroaniline 101-77-9, 4,4'-Methylenedianiline 101-79-1,  
 4-(4-Chlorophenoxy)aniline 106-44-5, 4-Methylphenol, reactions  
 109-00-2, 3-Hydroxypyridine 123-30-8, 4-Aminophenol 139-59-3,  
 4-Phenoxyaniline 150-76-5, 4-Methoxyphenol 288-32-4, Imidazole,  
 reactions 350-46-9, 1-Fluoro-4-nitrobenzene 400-74-8,  
 2-Fluoro-5-nitrobenzotrifluoride 580-17-6, 3-Aminoquinoline 585-79-5,  
 1-Bromo-3-nitrobenzene 591-27-5, 3-Aminophenol 610-35-5,  
 4-Hydroxyphthalic acid 620-95-1, 3-Benzylpyridine 622-58-2, 4-Tolyl  
 isocyanate 624-28-2, 2,5-Dibromopyridine 626-61-9, 4-Chloropyridine  
 626-64-2, 4-Hydroxypyridine 872-31-1, 3-Bromothiophene 1083-48-3,  
 4-(4-Nitrobenzyl)pyridine 1121-78-4, 5-Hydroxy-2-methylpyridine  
 1193-02-8, 4-Aminothiophenol 1195-45-5, 4-Fluorophenyl isocyanate  
 1849-36-1, 4-Nitrothiophenol 2033-89-8, 3,4-Dimethoxyphenol 2103-88-0,  
 2-Mercapto-4-phenylthiazole 3678-63-5, 4-Chloro-2-methylpyridine  
 4548-45-2, 2-Chloro-5-nitropyridine 4556-23-4, 4-Mercaptopyridine  
 4595-59-9, 5-Bromopyrimidine 7379-35-3, 4-Chloropyridine hydrochloride  
 7781-98-8, Ethyl 3-hydroxybenzoate 16588-75-3, 2-Methoxy-5-(trifluoromethyl)phenyl isocyanate 21101-60-0, 4-(4-Nitrophenylthio)phenol 22948-02-3, 3-Aminothiophenol 24424-99-5,  
 Di-tert-butyl dicarbonate 25267-27-0, Iodobutane 25475-67-6,  
 3-Aminoisoquinoline 27163-00-4, 4-[(4-Methoxyphenyl)methylamino]aniline  
 33252-26-5, 2-Amino-4-tert-butylpyridine 36265-31-3,  
 4-(4-Methylthiophenoxy)-1-nitrobenzene 41195-90-8, 2,3-Dichlorophenyl  
 isocyanate 41295-20-9, 4-(4-Methylphenoxy)aniline 53750-66-6,  
 4-Chloropyridine-2-carbonyl chloride 73322-01-7, 4-(2-Pyridinylthio)-1-nitrobenzene 74784-70-6, 2-Amino-5-(trifluoromethyl)pyridine  
 150009-83-9, 3-Amino-2-methoxyquinoline 170893-64-8,  
 4-(4-Pyridylcarbonyl)aniline 362688-26-4, 1-(4-Methylpiperazinyl)-3-aminoisoquinoline

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)


IT 432050-17-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

## (Uses)

(preparation of heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors)

RN 432050-17-4 HCAPLUS

CN Urea, N-(2,3-dichlorophenyl)-N'-[4-(1,1-dimethylethyl)-2-pyridinyl]- (9CI)  
(CA INDEX NAME)

=&gt; d all hitstr 176 tot

L76 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:701815 HCAPLUS

DN 141:185104

ED Entered STN: 27 Aug 2004

TI Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions

IN Rudolph, Amy E.; Rocha, Ricardo; Carretero, Oscar

PA USA

SO U.S. Pat. Appl. Publ., 107 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-415

ICS A61K031-401

INCL 514406000; 514423000

CC 1-8 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004167197	A1	20040826	US 2004-788220	20040226
	WO 2004075852	A2	20040910	WO 2004-US5609	20040226
	W:				
	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2004075857	A2	20040910	WO 2004-US5799	20040226
	W:				
	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

Search done by Noble Jarrell

PRAI US 2003-450529P P 20030226

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004167197	ICM	A61K031-415
	ICS	A61K031-401
	INCL	514406000; 514423000
US 2004167197	NCL	514/406.000; 514/423.000

AB This invention is directed generally to a method for treating a pathol. condition (particularly a cardiovascular condition (e.g., hypertension or heart failure) or a condition associated with a cardiovascular condition) using a p38-kinase inhibitor (e.g., a p38-kinase-inhibiting substituted pyrazole), and specifically a combination comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor (or "ACE inhibitor") for treating a cardiovascular condition. This invention also is directed generally to combinations comprising a p38-kinase inhibitor, and specifically to combinations comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor. This invention is further directed generally to pharmaceutical compns. comprising a p38-kinase inhibitor, and more specifically to compns. comprising the above-described combinations.

ST cardiovascular hypertension heart failure p38 kinase pyrazole ACE inhibitor

IT Heart, disease  
(arrhythmia; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Fibrosis  
Ischemia  
(cardiac; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Heart, disease  
(cardiomyopathy; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Brain, disease  
(cerebrovascular; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Anti-ischemic agents  
Antiarrhythmics  
Antihypertensives  
Blood vessel, disease  
Cardiovascular agents  
Cardiovascular system, disease  
Combination chemotherapy  
Drug interactions  
Edema  
Hypertension  
Kidney, disease

(compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Surgery  
(coronary angioplasty; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Thrombosis  
(coronary arterial; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Artery  
(coronary, angioplasty; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Artery, disease  
(coronary, thrombosis; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Artery  
(coronary; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Blood vessel, disease  
(endothelium; compns., combinations, and methods for treating

cardiovascular conditions and other associated conditions)

IT Heart, disease  
(failure; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Heart, disease  
(fibrosis; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Heart, disease  
(infarction; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Heart, disease  
(ischemia; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Heart, disease  
Inflammation  
(myocarditis; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Nerve, disease  
(neuropathy; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Eye, disease  
(retinopathy; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Endothelium  
(vascular, disease; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Blood vessel, disease  
Inflammation  
(vasculitis; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Heart, disease  
(ventricle, hypertrophy; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT Hypertrophy  
(ventricular; compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT 165245-96-5, p38-Kinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

IT 39698-78-7, Saralasin acetate 62571-86-2, Captopril 72873-74-6  
74258-86-9, Alacepril 75847-73-3, Enalapril 76420-72-9, Enalaprilat  
76547-98-3, Lisinopril 82768-85-2, Quinaprilat 82834-16-0, Perindopril  
83435-66-9, Delapril 83647-97-6, Spirapril 85441-61-8, Quinapril  
85856-54-8, Moveltipril 86541-75-5, Benazepril 87333-19-5, Ramipril  
87679-37-6, Trandolapril 88768-40-5, Cilazapril 89371-37-9, Imidapril  
95399-71-6, Fosinoprilat 98048-97-6, Fosinopril 103775-10-6, Moexipril  
111223-26-8, Cero-napril 111902-57-9, Temocapril 152121-30-7  
152121-47-6 164301-51-3 165806-09-7 165806-34-8 165806-48-4  
165806-51-9 165806-53-1 180869-32-3 188352-45-6 189442-43-1  
193746-75-7 200801-85-0 209410-46-8 215303-72-3 215306-39-1  
218145-98-3 218160-26-0 218162-38-0 219138-27-9 249937-52-8  
250123-27-4 271576-76-2 271576-77-3 271576-80-8 271576-82-0  
271576-83-1 271576-87-5 271576-89-7 271576-90-0 271576-91-1  
271576-92-2 271576-93-3 271577-04-9 271577-08-3 285983-48-4  
290357-24-3 304439-93-8 321351-00-2 335652-44-3 431062-04-3  
432042-02-9 432050-23-2 635724-76-4 635724-78-6  
635724-79-7 635724-80-0 635724-81-1 635724-82-2 635724-89-9  
635724-91-3 635724-92-4 635724-94-6 635724-95-7 635724-96-8  
635724-98-0 635724-99-1 635725-04-1 635725-05-2 635725-07-4  
635725-08-5 635725-09-6 635725-10-9 635725-11-0 635725-12-1  
635725-13-2 635725-16-5 635725-17-6 635725-20-1 635725-21-2  
635725-23-4 635725-24-5 635725-25-6 635725-26-7 635725-27-8  
635725-28-9 635725-29-0 635725-30-3 635725-31-4 635725-33-6  
635725-34-7 635725-35-8 635725-36-9 635725-37-0 635725-38-1  
635725-39-2 635725-40-5 635725-41-6 635725-42-7 635725-43-8

635725-44-9	635725-45-0	635725-46-1	635725-47-2	635725-48-3
635725-49-4	635725-50-7	635725-51-8	635725-53-0	635725-54-1
635725-55-2	635725-56-3	635725-57-4	635725-58-5	635725-59-6
635725-60-9	635725-61-0	635725-62-1	635725-63-2	635725-64-3
635725-65-4	635725-66-5	635725-67-6	635725-68-7	635725-69-8
635725-70-1	635725-71-2	635725-72-3	635725-73-4	635725-74-5
635725-75-6	635725-76-7	635725-77-8	635725-78-9	635725-79-0
635725-80-3	635725-81-4	635725-82-5	635725-83-6	635725-84-7
635725-85-8	635725-86-9	635725-87-0	635725-88-1	635725-89-2
635725-90-5	635725-91-6	635725-92-7	635725-93-8	635725-94-9
635725-95-0	635726-58-8	734522-98-6	740845-17-4	740845-18-5
740845-19-6	740845-20-9	740845-21-0	740845-23-2	740845-24-3
740845-25-4	740845-26-5	740845-68-5	740845-69-6	740845-70-9
740845-71-0	740845-72-1	740845-73-2	740845-74-3	740845-75-4
740845-76-5	740845-77-6	740845-78-7	740845-79-8	740845-80-1
740845-81-2				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(comps., combinations, and methods for treating cardiovascular  
conditions and other associated conditions)

IT 9015-82-1, Angiotensin-converting enzyme

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(inhibitors; comps., combinations, and methods for treating  
cardiovascular conditions and other associated conditions)


IT 432050-23-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(comps., combinations, and methods for treating cardiovascular  
conditions and other associated conditions)

RN 432050-23-2 HCAPLUS

CN Benzamide, 3-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-  
methyl- (9CI) (CA INDEX NAME)



=> b home

FILE 'HOME' ENTERED AT 12:11:56 ON 06 JUN 2005

=>